




2023 BIOPACIFIC CONFERENCE

Saturday, October 28, 2023, 8:00AM - 5:30PM
South San Francisco Conference Center
255 S Airport Blvd, South San Francisco, CA

**Collaboration, Acceleration,
Breakthrough, & Success**

PPROGRAM BOOKS OF PAST BIOPACIFIC CONFERENCES (1998-2022)



CABS Contact Information

Mailing Address
268 Bush Street, #1888
San Francisco, CA 94104, USA

Website
<http://www.cabsweb.org>

Emails
For General information
Info@CABSweb.org

Membership
Membership@CABSweb.org

For Fundraising
Fundraising@CABSweb.org

Program Book Production
Chief Editor
Zhiyong Yang
Graphic Design
Xiaojun Li
2023 BioPacific Conference Organizing Committee



cabsweb.org

TABLE OF CONTENTS

- 2** 2023 BioPacific Conference Sponsors
- 4** CABS Mission Statement
- 5** About CABS
- 6** Opening Remarks
 - Remarks from President of CABS
 - Remarks from President-Elect of CABS
- 8** CABS Leadership
- 9** 2023 BioPacific Conference Organizing Committee
- 10** 2022 CABS Service Awards
- 11** Highlights of 2022 BioPacific Conference
- 13** Conference Floor Plan
- 14** Conference Agenda
- 16** Speakers
 - K. Fong Award Speaker
 - Podium Speakers
 - Panel Speakers
 - Lunch & Learn Session Speakers
- 30** 2022-2023 Selected CABS Activities
- 43** More about Sponsors

**English is the official working language of the Conference.*

BIOPACIFIC CONFERENCE 2023 SPONSORS



Long-Term Partner



Diamond Sponsor



Platinum Sponsor



Gold Sponsors



Silver Sponsors



Exhibitors



Media Partners





WHO WE ARE

The Chinese American Bio/pharmaceutical Society (CABS) is a non-profit organization for professionals in the biopharmaceutical industry. CABS is headquartered in the San Francisco Bay Area, California. This is the home of Silicon Valley, the birthplace of biotechnology and one of the largest biomedical clusters with the highest venture capital investment in the world. There are more than a thousand biopharmaceutical/biotech companies in this area, including several large biopharmaceutical companies such as Amgen, Genentech and Gilead. CABS is a highly influential association with more than 3000 members and 20000 subscribers in the life sciences industry. About 70% of our members have PhD degrees relating to life sciences. A considerable proportion of the members hold senior research and management positions in US-based and multi-national life sciences corporations. Many of our members are experts and leaders, innovative entrepreneurs, lawyers and venture capitalists, or investors in the life sciences sector. CABS is one of North America's most active largest biopharmaceutical associations. We organize many activities to promote international collaborations in life sciences. In addition to year-round technology and business seminars, the annual BioPacific Conference organized by CABS is a highly anticipated event that attracts hundreds of biopharmaceutical professionals and business leaders.



Our Vision


- To serve as the gateway linking life science professionals & organizations in the U.S. & Pacific Rim Countries

Our Mission

- To SERVE life science professionals to promote professional interactions locally and across the Pacific
- To FOSTER business opportunities and exchanges in the life science industry between the U.S. and Pacific Rim countries
- To PROMOTE public awareness of progress and development in the life sciences industry
- To COLLABORATE with other organizations in areas of mutual interest

CABS Member Demographics

- Life science professionals from a broad range of experience levels
- Large percentage of members hold senior or executive positions
- Numerous entrepreneurs founded life science companies
- Continue to attract talents from academic institutions such as UCB, Stanford, UCSF, etc





Yuying (Kate) You, PhD, JD
President of CABS

Remarks from the President of CABS

Dear CABS members and friends,

Welcome to the 2023 BioPacific Conference, the 24th annual conference of the Chinese-American Bio/Pharmaceutical Society (CABS)!

First, I would like to express my deep gratitude to President-Elect, Dr. Jessica Sun, the entire organizing committee, and our volunteers who have dedicated months of tireless effort to make this conference possible.

Over the past year, the biopharmaceutical industry has faced a mix of challenges and opportunities. On the one hand, numerous opportunities are emerging in 2023. Advances in gene and cell therapies offer the promise of transformative treatments for a broad range of diseases. The integration of artificial intelligence and machine learning have been accelerating drug discovery, and are potentially reducing development costs and timelines. Partnerships between biopharma companies, tech firms, and research institutions have the potential to drive collaborative solutions and disruptive innovations.

On the flip side, while the field is experiencing tremendous advancements, these breakthroughs often come with substantial hurdles. Challenges include the escalating costs of research and development, prolonged timelines for drug approvals, drug resistance, biologics manufacturing complexities, and an increasingly complex regulatory landscape. Navigating these challenges while capitalizing on the multitude of opportunities will be crucial for the continued success of the biopharmaceutical sector. Today, we have the great honor of welcoming distinguished speakers who will generously share their invaluable insights on some of these pivotal topics.

We are deeply honored to welcome Dr. Corey Goodman as this year's K. Fong Awardee. With a distinguished career that spans as a professor, serial entrepreneur, pharmaceutical executive, and venture capitalist, he brings a wealth of experience and knowledge to share his remarkable journey with us.

As you may know, CABS operates as a non-profit organization entirely driven by dedicated volunteers. It has been my great honor to work with this Executive Council during our term. Their boundless energy, innovative thinking, and unwavering commitment to excellence have been truly remarkable. In addition to their crucial role in organizing this prestigious conference, they've orchestrated a series of highly successful science, technology, career, professional, and social events for our community. I am immensely proud of our team.

Our inaugural event of the year, the 2023 CABS Investor Forum in January, drew nearly 200 investors, entrepreneurs, and professionals. Throughout the year, our Science and Technology Committee (STC) and International Collaboration Committee (ICC) organized three educational seminars, featuring leaders from academic and industry discussing trends in BioPharma, gene editing, and CDMO opportunities and challenges. These seminars consistently attracted a packed audience of scientists, researchers, and professionals.

We are committed to nurturing a thriving community for our emerging leaders. Our Business and Career Development Committee (BCD) recently introduced a highly sought-after career-building series, including the highly acclaimed seminar "Strategically Mapping Your Career." In addition, our Career Advisory Network (CAN) team has expanded our flagship mentoring program by doubling the number of mentors to create an even more comprehensive support network.

This year has been filled with enjoyable moments. Our Social Life Committee (SLC) organized an unforgettable New Year Party and a delightfully entertaining summer BBQ. Additionally, we successfully revived our dragon boat team, and we're thrilled to share that we reached an impressive third place!

If you are not a member yet, we welcome you to join us! I hope that you all enjoy today's conference.

Yuying (Kate) You, PhD, JD
President of CABS



Jessica Sun, MD, PhD
*Chair of 2023 BioPacific
Conference Organizing
Committee,
President-Elect of CABS*

Remarks from the Chair of 2023 BioPacific Conference Organizing Committee, President-Elect of CABS

A warm welcome to the 2023 BioPacific Conference! I am deeply honored to serve as the Organizing Committee Chair, and it is a privilege to work alongside this brilliant team to bring you the 2023 BioPacific Conference, also known as the 24th Annual Conference of the Chinese American Bio/Pharmaceutical Society (CABS).

This year holds special significance as we celebrate the 25th anniversary of CABS. The theme of our conference, "Collaboration, Acceleration, Breakthrough, & Success - 25 years of CABS," beautifully encapsulates our journey. Over the past 25 years, we have grown, learned, and achieved together.

Collaboration has always been at the heart of CABS. It's the unity of our members, their expertise, and their commitment to working together that has advanced us. Through this collaboration, we aim to accelerate progress as well as business opportunities in the fields of life sciences, promoting innovation and discovery. Our dedication to pushing boundaries and embracing challenges has led to numerous breakthroughs that have had an impact on the industry. And, of course, all these efforts have resulted in incredible successes, both for our members individually and for CABS as an organization.

As we take a moment to reflect on our past accomplishments, we find ourselves facing a sky filled with pressing questions in the biopharmaceutical industry. The 2023 BioPacific Conference, with its stellar assembly of speakers and panel discussions, promises to be a meeting point of groundbreaking ideas, pioneering research, and unparalleled networking opportunities.

In honor of the 10th anniversary of the CABS K. Fong Award in Life Sciences, we extend our heartfelt congratulations to Dr. Corey Goodman, this year's awardee for his outstanding contributions to science, education, entrepreneurship, and venture capital. He will share his personal journey, from academia to biotech and pharma, illustrating how great science can lead to impactful medicine.

We are delighted to have Dr. Raymond Deshaies and Dr. William DeGrado as our distinguished keynote speakers. Dr. Deshaies will delve into the challenges, opportunities, and Amgen's innovative approaches in developing the next generation of multispecific small molecule and biologic medicines. Dr. DeGrado, who coined the term "de novo protein design," will share his profound insights into the remarkable progress made in creating predictable protein structures and functions.

Our esteemed lineup continues with Dr. Cheng Liu, who will introduce the ARTEMIS Cell Receptor Platform for the treatment of solid tumors, and Dr. Dinesh Patel, who will elucidate the science and art of oral peptides, showcasing the discovery of the IL-23 receptor antagonist. Dr. Biaoxiao Cui will shed light on her cutting-edge research regarding membrane curvature and the discovery of a new type of integrin-mediated cell adhesion. Furthermore, Dr. Philip Patten will take us on the journey of DiCE Molecules, highlighting their innovative approach to developing small molecules. Additionally, we will have panel discussions on investment strategy and AI in drug discovery. Finally, a panel of past CABS presidents will share personal growth stories in a changing environment.

We thank our speakers, sponsors, the Organizing Committee, and volunteers for their invaluable contributions. To our attendees, your participation and support are deeply appreciated. We wish you an enjoyable and enriching experience at the 2023 BioPacific Conference. Let us embark on this journey of Collaboration, Acceleration, Breakthrough, & Success together!

Jessica Sun, MD, PhD
*Chair of 2023 BioPacific Conference Organizing Committee
President-Elect of CABS*

CABS Leadership



President-Elect
Jessica Sun, MD, PhD
Terremoto Biosciences



President
Yuying "Kate" You, PhD, JD
Morrison Foerster LLP



Past President
Carrie Wang, MD
ARC Medical

Board of Directors

Carrie Wang, MD
Yang Tian, PhD
Yan Wang, PhD
Alex J. Zhang, PhD, MBA
Cheni Kwok, PhD, CLP
Jiangwen Majeti, PhD, MBA
Alan Hao, PhD
Zhonghua Pei, PhD
Wentao Zhang, PhD
Janet Xiao, PhD, JD
Shichang Miao, PhD
Jing-Shan Hu, PhD
Cheng Liu, PhD
John Wang, PhD

2023 Executive Council

Office of the President

- **President:** Yuying "Kate" You, PhD, JD, Patent Attorney, Morrison Foerster LLP.
- **President-Elect:** Jessica Sun, MD, PhD Sr. Director, Terremoto Biosciences
- **Past President:** Carrie Wang, MD, VP Preclinical, ARC Medical

Office of Operations (O2)

- **Co-Chair:** Sihong Zhou, Sr. Scientist, Sutro Biopharma; Zhiyong Yang, PhD, Scientist, Genentech
- **Member:** Shicheng Guo, PhD, Director, Arrowhead Pharmaceuticals; Pingdong Ai, MS, Sr. Director, Vertex Pharmaceuticals; Yang Ma, Student

Membership (MEM)

- **Co-Chair:** Vivian Liu, PhD, Lab Director, Novogene; Wenjia Gu, PhD, Associate Scientist, Sutro Biopharma
- **Member:** Suping Ren, MS, Lab Manager, Johnson & Johnson

Public Relations & Communications (PRC)

- **Co-Chair:** Liang He, PhD, Postdoc, UCSF; Guanghui Han, PhD, Sr. Director, Innomics
- **Member:** Shu Huang, PhD, Twist Bioscience; Junjun Cheng, PhD, Sr. Scientist, Riboscience; Yiquan Liu, PhD, Sr. Research Scientist, Gilead Sciences

Alliance Management Committee (AMC)

- **Co-Chair:** Yanan Wang, PhD, Sr. Scientist, QLSF Biotherapeutics; Lu Lu, MS, Sr. Director, MicuRx Pharmaceutical
- **Member:** Denna Kwang, BS, Sr. Associate Scientist, Johnson and Johnson; Yu Chen, PhD, Sr. Clinic Research Coordinator, Palo Alto Veterans Institute for Research; Yuki Yang, BS, Research Associate, Vaxart; Amy Yang, MD, Staff Scientist, Sangamo; Katherine Guan, BS, Associate Scientist II, Janssen R&D; Xuefei Tian, MS, Scientist, Genentech; Eric Liu, MS, Lab Manager, APstem Therapeutics

Science & Technology Committee (STC)

- **Co-Chair:** Yan Wang, PhD, Director, ChemPartner; Alex Yang, PhD, Sr. Scientist, VIR Biotechnology

2023 BioPacific Conference Organizing Committee

Jessica Sun, PhD, Chair; President-Elect, CABS; Sr. Director, Terremoto
Yuying "Kate" You, PhD, JD, Patent Attorney, Morrison Foerster LLP.
Liang He, PhD, postdoc, UCSF
Shicheng Guo, PhD, Director, Arrowhead
Yan Wang, PhD, Director, ChemPartner
Denna Kwang, Sr. Associate Scientist, Johnson & Johnson
Ella Li, PhD, Founder & CEO, H7 BioCapital
Yuda Chen, PhD, Postdoc, UCSF
Zhiqing Wang, PhD, Scientist II, Codexis
Vivian Liu, PhD, Lab Director, Novogene
Lin Wang, PhD, Director, Gilead Sciences
Lu Lu, MS, Sr. Director, MicuRx
Carrie Wang, MD, VP, ARC Medical

Li Guan, PhD, Research Scientist, Stanford
Suping Ren, MS, Lab Manager, Johnson & Johnson
Yiquan Liu, PhD, Sr. Research Scientist, Gilead Sciences
Yuan Sun, PhD, Associate Principal Scientist, Merck
Zhiyong Yang, PhD, Scientist, Genentech
Tao Geng, MD, Principal Scientist, Nkarta
Xi Fang, PhD, Founding Partner, Button
Wenjia Gu, PhD, Associate Scientist, Sutro Biopharma
Yanan Wang, PhD, Sr. Scientist, QLSF Biotherapeutics
Guanghui Han, PhD, Sr. Director, Innomics

Sihong Zhou, Sr. Scientist, Sutro Biopharma
Junjun Cheng, PhD, Sr. Scientist, Riboscience
Kay Tong, MA, Head of Quality System and Compliance, Sana Biotechnology
Kaiqing Zhang, PhD, Business Development Manager, Biocytogen
Yu Yang, MS, CEO, Hanhai Silicon Valley Center
Ava Song, MS, Associate Consultant, C Space
Shu Huang, PhD, Twist Bioscience
Zehui Du, Student, Peking University & UC Berkeley
Xuexiang Zhang, Locagen Therapeutics

International Collaboration Committee (ICC)

- **Co-Chair:** Hesong Sun, PhD, Vice President, Huamai Medical; Yu Yang, MS, CEO, Hanhai Silicon Valley Center

Business & Career Development Committee (BCD)

- **Co-Chair:** Kay Tong, MA, Head of Quality System and Compliance, Sana Biotechnology; Liping Meng, PhD, Sr. Research Scientist, Gilead Sciences
- **Chair of the CAN Program:** Xiaojie Chen, PhD, Consultant, Afasci; Jack Zhu, MBA, Associate Director, Gilead
- **E-Club Co-Chair:** Xi Fang, PhD, Managing Partner, Button Capital
- **Member:** Mingdian Tan, PhD, Postdoc, Stanford
- **Advisor:** Ella Li, PhD, Founder & CEO, H7 BioCapital

Social Life Committee (SLC)


- **Co-Chair:** Li Wang, Arcus Biosciences; Xinxin Li, MSPH, VP, MyBioGate
- **Member:** Crystal Tan, MS, San Francisco General Hospital

Web Master

Shicheng Guo, PhD, Arrowhead
Pingdong Ai, Vertex
Michael Lin, CTO 911

Accountant

Yao Long



CABS 2022

Service Awards

Five-Year Extraordinary Leadership

Recognizing EC members for more than 5 years of service at CABS committees.

Award: Five years' membership and free pass to all CABS activities.

Michael Xie

Three-Year Extraordinary Leadership

Recognizing EC members for more than 3 years of service at CABS committees.

Award: Three years' membership and free pass to all CABS activities.

Suping Ren, Li Wang, Maggie Zhou, Weijie Lan, Zhiyong Yang

Co-Chair Contribution Award

Contributions in the 2021-2022 term of CABS executive council as a co-chair.

Weixing Chen, AMC; Jessica Sun, AMC; Danielle Liu, CAN Program; Liping Meng, BCD;

Kay Tong, BCD; Hesong Sun, ICC; Xi Fang, ICC; Dong Su, MEM

Outstanding EC Award

Contributions in the 2021-2022 term of CABS executive council as a member.

Xiaojie Chen, Yu Yang, Zhiyong Yang, Ning Zhu, Junjun Cheng

Outstanding EC Award

Contributions in the 2021-2022 term of CABS executive council as a volunteer.

Yanan Wang, Vivian Liu, Liang He, Ella Li,

Denna Kwang, Lifei (Alex) Yang, Wenjia Gu, Xinxin Li, Li Guan

2022 BioPacific Conference Highlights





2023 BioPacific Conference
South San Francisco Conference Center
 255 S Airport Blvd, South San Francisco, CA 94080

Floor Plan



2023 CABS BIOPACIFIC CONFERENCE

AGENDA

Collaboration, Acceleration, Breakthrough, & Success

* English is the official working language of the Conference.

8:00 AM – 8:40 AM Registration

8:40 AM – 8:45 AM Welcome Remarks

Jessica Sun, MD, PhD, **President-Elect of CABS**, Chair of Organizing Committee of 2023 BioPacific Conference

8:45 AM – 8:50 AM State of the Society

Yuying "Kate" You, PhD, JD, **President of CABS**

Morning Session 1 – Session Chair: Yanan Wang, PhD, CABS Executive Council

8:50 AM – 9:25 AM Keynote Speech: Multispecific Medicines for the Future

Ray Deshaies, PhD, Sr. Vice President, Global Research, Amgen

9:25 AM – 9:55 AM Integrin-Mediated Cell Adhesion and Its Linkage to Fibrosis

Bianxiao Cui, PhD, Professor, Stanford

9:55 AM – 10:05 AM Considerations and Case Study on Drug Development and Commercialization

Wei Huang, President, Henlius; Chairman, Aton Biotech

10:05 AM – 10:25 AM Coffee Break, Network, & Exhibition

Morning Session 2 – Session Chair: Lu Lu, MS, CABS Executive Council

10:25 AM – 10:35 AM 2023 CABS K. Fong Award in Life Sciences

Moderator: Wentao Zhang, PhD, Founder & President, Quintara Discovery; **President of CABS 2012-13**

Presenter: Kenneth Fong, PhD, Chairman, Kenson Ventures

Awardee: Corey Goodman, PhD, Managing Partner, venBio; Adjunct Professor, UC Berkeley

10:35 AM – 11:10 AM Acceptance Speech: Turning Great Science into Impactful Medicine: A Journey from Academia to Biotech and Pharma

Corey Goodman, PhD, Managing Partner, venBio; Adjunct Professor, UC Berkeley

11:10 AM – 11:50 AM Panel Discussion: Ask the Investor: A View into the Future of Life Science Innovation

Moderator: Ella Li, PhD, Founder & CEO, H7 BioCapital; **CABS Executive Council**

Panelists:

- Ronjon Nag, PhD, Managing Director and Founder, R42 Group; Adjunct Professor, Stanford
- Ted Hou, PhD, Founding Partner, Berkeley Catalyst Fund
- Michael Ryan, MHSA, FACHE, FACHT, Managing Partner, EIG/MGR Capital
- Tao Fu, MS, MBA, Founder and CEO, Attovia Therapeutics; Venture Partner, Frazier Life Sciences

11:50 AM – 12:20 PM DiCE Molecules – Lessons Learned from Revisiting an "Old Technology" and Taking a Non-Traditional Approach to Financing and Exit

Phillip A. Patten, PhD, CSO, Initial Therapeutics

12:20 PM – 1:35 PM Lunch & Learn

12:40 PM – 12:50 PM Concurrent Session A (Breakout Room A), Chair: Denna Kwang, CABS Executive Council Empowering Drug Discovery and Development with Pharmaron's Global Integrated Offering: Quality, Speed, Flexibility, One-Stop Solution

Liyu Wu, PhD, Sr. Director of Business Development, Pharmaron

12:50 PM – 1:00 PM Contract Vivarium Facilities: Biotech's Fastest Emerging Option for Preclinical Animal Studies

Bill Glencross, Director of Sales, Mispro

1:00 PM – 1:10 PM How JLake Could Help Cross-Border Entrepreneurs

Yifu Liu, MFin, Executive Director, JLake

12:40 PM – 12:50 PM Concurrent Session B (Breakout Room B), Chair: Katherine Guan, CABS Executive Council GenScript's One-Stop Solution Takes Your Research to the Next-Level

Karen Han, PhD, Field Based Account Manager, GenScript

12:50 PM – 1:00 PM Building Next-Gen Biologics Leveraging Industry-Leading Fully Human Heavy Chain Only Antibody Platforms

Jiyong Zhang, PhD, Head of Business Development, Nona Biosciences

1:00 PM – 1:10 PM First-to-Market Recombinant Proteins & Enzymes for Tomorrow's Biopharma & Diagnostic Innovations

Yujiao Zhang, PhD, Product Marketing Scientist, KACTUS

Afternoon Session 1 – Session Chair: Shicheng Guo, PhD, CABS Executive Council

1:35 PM - 2:10 PM Keynote Speech: De novo Protein Design of Functional Proteins

William DeGrado, PhD, Professor, UCSF

2:10 PM – 2:40 PM Converging Biotech Innovation into Pharma Partnership: The Science & Art of Oral Peptide Therapeutics

Dinesh Patel, PhD, Director, President & CEO, Protagonist Therapeutics

2:40 PM - 3:20 PM Panel Discussion: Leveraging Artificial Intelligence in Drug Discovery: Opportunities and Challenges

Moderator: Cheni Kwok, PhD, CLP, Managing Partner, Linear Dreams; **President of CABS 2016-17**

Panelists:

- Nicolas Tilmans, PhD, Founder & CEO, Anagenex
- Stephanie Sharron, JD, Partner, Morrison & Foerster LLP
- Pek Lum, PhD, Founder, CEO, Auransa

3:20 PM - 3:50 PM Coffee Break, Network & Exhibition

Afternoon Session 2 – Session Chair: Liang He, PhD, CABS Executive Council

3:50 PM - 4:20 PM Treating Solid Tumors with ARTEMIS T-Cells Engineered with Antibody T-Cell Receptor (AbTCR)

Cheng Liu, PhD, President & CEO, Eureka; **President of CABS 2004-05**

4:20 PM – 5:00 PM Panel Discussion: To Stay or to Go – Navigating Career Growth in an Ever Changing Environment

Moderator: Jen Majeti, PhD, MBA, Board Member, BeyondSpring; **President of CABS 2015-16**

Panelists:

- Jing-Shan "Jennifer" Hu, PhD, Former Sr. Advisor & Founding Partner, Qiming U.S. Healthcare Fund; **President of CABS 2006-07**
- Shichang Miao, PhD, Partner, Rivermount Fund; **President of CABS 2009-10**
- Janet Xiao, PhD, JD, Partner, Morrison & Foerster LLP; **President of CABS 2011-12**
- Zhonghua Pei, PhD, Sr. Vice President, Neuron23; **President of CABS 2013-14**
- Alex J Zhang, PhD, MBA, Founder & CEO, OneTwenty Therapeutics; **President of CABS 2017-18**

5:00 PM – 5:10 PM Closing Remarks

Keting Chu, PhD, Founder & CEO, Bluejay Therapeutics; **Founding President of CABS 1998-99**

5:10 PM – 5:30 PM 25th Anniversary Special: I LOVE CABS Draw (AirPods, iWatch, iPad, CABS Lifetime Membership, and 2024 CABS BioPacific Conference Free Pass)

Announcing 2023 CABS K. Fong Award in Life Sciences



CABS honors Dr. Corey Goodman's exceptional accomplishments and profound impact on the life sciences industry and academia. His visionary leadership, groundbreaking research, and dedication to healthcare have left an indelible mark on the life sciences community.

South San Francisco, CA - CABS proudly announces Dr. Corey Goodman as the recipient of the prestigious 2023 CABS K. Fong Award in Life Sciences, commemorating the 10th anniversary of this honored distinction. This esteemed award recognizes Dr. Goodman's outstanding contributions to science, education, entrepreneurship, and venture capital. The award will be presented at the 2023 BioPacific Conference.

A celebrated figure in the scientific community, Dr. Corey Goodman's journey has been nothing short of remarkable. He obtained his BS from Stanford University and earned his PhD from UC Berkeley. He spent 25 years as a Professor of Biology at Stanford and a Professor of Neurobiology at Berkeley where he was a Howard Hughes Medical Institute Investigator, Co-Founder of the Wills Neuroscience Institute, and achieved an h-index of 131. Dr. Goodman is currently the Adjunct Professor of Neuroscience at Berkeley.

He is an elected member of the National Academy of Sciences, American Academy of Arts and Sciences, and American Philosophical Society, and a recipient of many honors, including the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March-of-Dimes Prize, and Gruber Prize in Neuroscience.

Dr. Goodman's achievements extend beyond academia. He transitioned from research to the biotechnology industry, bridging the gap between scientific discoveries and impactful medicines. He co-founded eight biotech companies, notably Exelixis being the first one; he served as the CEO of Renovis, leading the company to go public and achieve a successful acquisition by Evotec. At Pfizer, he was President of the Biotherapeutics and Bioinnovation Center and a member of the executive leadership team.

As Managing Partner of venBio, a venture capital firm he co-founded, Dr. Goodman fosters groundbreaking scientific advancements. He chairs the boards of leading biotechnology companies like ALX Oncology, Tallac, Axonis, Attralus, MindRhythm, Axent, and Insamo. Additionally, he is a valued member of the Boards of NFlection and FogPharma. He chaired Labrys Biologics, a company he founded, until its acquisition by Teva. The Labrys drug, called Ajovy, is a CGRP antibody for chronic migraine that was approved by the FDA in 2018.

His commitment to public service is commendable. As the former Chair of the California Council on Science and Technology, Dr. Goodman provided invaluable guidance to the Governor and State Legislature. He also served as the former Chair of the National Research Council's (NAS) Board on Life Sciences, advising the Federal Government on critical matters.

CABS honors Dr. Corey Goodman's exceptional accomplishments and profound impact on the life sciences industry and academia. His visionary leadership, groundbreaking research, and dedication to healthcare have left an indelible mark on the scientific community.

About CABS K. Fong Award in Life Sciences

The CABS K. Fong Award in Life Sciences is an esteemed annual recognition presented to individuals who have made exceptional contributions to the fields of life sciences and the biopharmaceutical industry including outstanding scientific findings, recognized efforts in promoting life science education and initiatives in improving life science community, and those who bring therapeutic breakthroughs to the market and improve healthcare and quality of life. Candidates eligible for this award must be nominated by an active member of CABS. Selection criteria are based on candidate's accomplishments in life sciences and contribution to the life science community, including one or more of the following:

- Proven achievements in therapeutic breakthroughs (including discovery, process, or clinical development), diagnostics or research reagent/equipment markets.
- Significant contribution to the promotion of academic and industrial R&D in biomedical sciences and applications.
- Significant contribution to the CABS community and promotion of international collaborations in life sciences.

Past recipients of CABS K. Fong Awards

2022 Scott Liu, PhD, Founder and CEO, HanchorBio, for his outstanding and pioneering contribution to the development of multiple biologic products from research to launch.

2021 John O. Link, PhD, Vice President of Gilead Sciences and Xian-Ping Lu, PhD, Chairman, CEO of Shenzhen Chipscreen Biosciences Co., LTD, for their extraordinary achievements in research, entrepreneurship, and innovation.

2019 John V. Oyler, PhD, Chairman, Co-Found and CEO of BeiGene, for his entrepreneurship and business leadership to establish BeiGene as a world-class biopharmaceutical company.

2018 Yuling Luo, PhD, Founder, CEO and Chairman of Alamar Biosciences, and Guoliang Yu, PhD, Executive Chairman of Crown Bioscience, for their successful serial entrepreneurship in the life science business.

2017 Yinxiang Wang, PhD, Co-founder and CSO of Beta Pharma, for his role in leading development and commercialization of Commana[®], the first small molecule oncology drug specifically targeting cancer cells that was completely developed in China; and Edgar Engleman, PhD, for his pioneering research that was the basis of the Sipuleucel-T (Provenge) prostate cancer vaccine, the first active immunotherapy for cancer to be approved by the FDA.

2016 Gerald Chan, PhD, co-founder of Morningside, for his extraordinary vision and leadership in cultivating a generation of successful entrepreneurs and life sciences companies.

2015 Irving Weissman, PhD, Stanford University, for his pioneering work in stem cell research.

2014 Ge Li, PhD, Founder and CEO of Wuxi Apptec, for creating and shaping the CRO business model in China; and Hing L. Sham, PhD, formerly of Abbott for his leading role in the discovery of life-saving HIV protease inhibitors, ritonavir and lopinavir.

2013 Peter Hirth, PhD, Plexxikon & Sugen for his pivotal role in advancing 4 successful drugs to the market, and Jean Cui, PhD, formerly of Pfizer as the lead designer and investigator of crizotinib, a successful kinase inhibiting drug used in personalized medicine.


About Kenneth Fong, PhD

Dr. Kenneth Fong has spent the last 39 years in the biotech industry after completing his academic pursuit in biomedical research.

He is best known for founding the biotech company, Clontech in 1984 which he built into one of the largest biomedical tool companies founded by an Asian American in the US (400 employees including 65 PhD scientists). Clontech was acquired by Becton Dickinson in 1999, and Ken has continued his career as a venture capitalist with Kenson Ventures that he founded. He has since cultivated 12 highly successful entrepreneurs, advising them and working with them on the growth of their companies.

Currently, he sits on the board of 4 biotech companies and he was intimately involved with the M/A and IPO of more than 15 companies that are worth more than \$7 billion. These companies range from research tools, medical diagnostics and drug development. In almost all cases, Ken has been instrumental in providing strategies for sustainable growth, value creation and liquidity. Those successful entrepreneurs have moved on to assume leadership in other start-up and mid-sized companies, which in turn led to a new generation of entrepreneurs.

Ken has held a number of leadership positions over the years. He served as the President of the Society of Chinese Bioscientists in North America (2006-07) and President of the Bay Area Asian American Manufacturers' Association (AAMA, 1987). He was also a member of the Board of Trustees of the California State University System (2006-13). His philanthropic interests include scholarships to San Francisco State University, the Kenneth Fong-Hearst endowed scholarships to the CSU system and 40 student scholarships to Peking University. In 2003, he was involved with establishing the Fong Optometry and Medical Library at UC Berkeley, and more recently an endowed professorship at Stanford University and a technology translation endowed fund at San Francisco State University.



2023 CABS K. Fong Award in Life Sciences Recipient



Corey Goodman, PhD
Managing Partner, venBio;
Adjunct Professor, UC Berkeley



Turning Great Science into Impactful Medicine: A Journey from Academia to Biotech and Pharma

Corey Goodman is a scientist, educator, entrepreneur, and venture capitalist. He received his BS from Stanford and PhD from UC Berkeley. He spent 25 years as Professor of Biology at Stanford and Professor of Neurobiology at Berkeley where he was Howard Hughes Medical Institute Investigator, co-founder of the Wills Neuroscience Institute, and with an h-index of 131. He is currently an Adjunct Professor of Neuroscience at Berkeley. He is an elected member of the National Academy of Sciences, American Academy of Arts and Sciences, and American Philosophical Society, and recipient of many honors including the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March-of-Dimes Prize, and Gruber Prize in Neuroscience. He moved from academia to biotechnology to help turn great science into impactful medicine. He co-founded eight biotech companies (the first being Exelixis) and led one of them (Renovis) as CEO from a private to public company until its acquisition by Evotec. At Pfizer he was President of the Biotherapeutics and Bioinnovation Center and a member of the executive leadership team. Today he is Managing Partner of venBio, a venture capital firm he co-founded. He is Chair of the Board of ALX Oncology, Tallac, Axonis, Attralus, MindRhythm, Axent, and Insamo, and a member of the Board of NFlection and FogPharma. His public service has been at the interface of science and public policy, including (amongst other roles) being former Chair of the California Council on Science and Technology (advising the Governor and State Legislature), and former Chair of the National Research Council's (NAS) Board on Life Sciences (advising the Federal Government).

Abstract:

Throughout my career, I've had the opportunity to live my life in chapters — from academic professor to biotech entrepreneur and CEO to Pharma executive to venture capitalist. Along the way, I've done my fair share of public service at the interface of public policy and science and innovation at the federal and state level. Those different roles have provided me with a multi-faceted perspective on the life sciences ecosystem from basic science to approved therapeutics. My talk will draw from various examples along that journey to focus on the health of the life science innovation ecosystem today and the opportunities for the next generation of entrepreneurs.



Moderator
Wentao Zhang, PhD
Founder and President,
Quintara Discovery;
President of CABS 2012-2013



Dr. Wentao Zhang is Founder and President of Quintara Discovery, a wholly owned subsidiary of Frontage, and Executive Vice President of Frontage West Coast Operations and leads its efforts in Discovery Services.

Dr. Zhang joined Frontage in 2021 through the acquisition of Quintara Discovery, a drug discovery service company he founded in the San Francisco Bay Area in 2012. Before founding Quintara, Dr. Zhang was Sr. Director of New Lead Discovery at Exelixis where he managed key drug discovery platforms and functions that included compound repository, assay development and high-throughput screening, lead optimization, DMPK operations, and safety pharmacology.

Dr. Zhang made significant contributions to over twenty compounds from discovery to clinical development, including the discovery, *in vitro* ADME and pharmacological characterizations of two FDA approved small molecule drugs. Dr. Zhang has been an *ad hoc* member of the NIH study section on assay development & HTS.

Dr. Zhang received his PhD degree in biophysical chemistry at University of Wisconsin-Madison and a BS degree in chemistry from Peking University. He has also conducted research in DNA replication as a postdoctoral fellow at UC Berkeley. Dr. Zhang is the past president (2012-2013) and currently a member of the board of directors of CABS.



Keynote Speaker

Ray Deshaies, PhD
Sr. Vice President,
Global Research, Amgen



Multispecific Medicines for the Future

Raymond Deshaies is the Sr. Vice President of Global Research at Amgen. Prior to joining Amgen, Deshaies served as a professor at the California Institute of Technology (Caltech) and an executive officer in Caltech's Division of Biology and Biological Engineering.

He was also an investigator at the Howard Hughes Medical Institute. He has published over 150 papers on various subjects including discoveries of Sec61 translocon, cullin-RING ubiquitin ligases, and proteolysis-targeting chimeric molecules (PROTACs). In addition to his academic work, Deshaies co-founded Proteolix in 2003 and Cleave Therapeutics in 2011.

Deshaies holds a bachelor's degree in biochemistry from Cornell University and a PhD in biochemistry from UC Berkeley. He is also a member of the American Academy of Arts and Sciences and National Academy of Sciences. In 2022, Fierce Pharma named Deshaies as one of the most influential people in biopharma. He received the 2023 Jacob and Louise Gabbay Award in Biotechnology and Medicine along with Yale University professor, Craig Crews, for their pioneering work on PROTACs.

Abstract:

Collectively, the biopharmaceutical industry has had an enormous impact on human health through the discovery and development of numerous safe and effective molecular medicines, including both small molecules and biologics. This success has, inevitably, raised the bar on expectations for future medicines. To thrive going forward, our industry will have to make medicines that are even safer and more effective than what came before. This is a tall order, given the relatively small number of high-conviction, accessible targets in most diseases. Nevertheless, opportunities abound, provided that we can surmount the key barriers that restrain many drug development efforts. These include overcoming biological redundancy, managing on-target toxicity/therapeutic index, and conquering so-called undruggable targets. Multispecific medicines that either attack multiple targets simultaneously, localize the action of a drug, or link targets to natural effectors offer a new approach to vanquish these perennial foes. In my presentation I will review the challenges and opportunities and describe approaches that Amgen is taking to develop the next generation of multispecific small molecule and biologic medicines for the benefit of future patients.



Keynote Speaker

William DeGrado, PhD
Professor, UCSF



De novo Protein Design of Functional Proteins

William (Bill) DeGrado's work focuses on the design of small molecule drugs, peptides, and proteins to address biological and mechanistic questions. Since 2011, Bill has been a professor in the Department of Pharmaceutical Chemistry at the UCSF, where he is also a member of the Cardiovascular Research Institute and an adjunct member of the Institute for Neurodegenerative Diseases. He is also a Chair Professor at Sungkyunkwan University (Korea). Prior to UCSF, he was a member of DuPont Central Research and DuPont Merck Pharmaceutical Company from 1981 to 1996 and the Raiziss Professor in the Department of Biochemistry and Biophysics at the University of Pennsylvania (1996 – 2011). Bill was also co-founder of Pliant, a company devoted to finding cures for fibrotic diseases (<http://pliantr.com>). Some of Bill's research interests include: *de novo* design of proteins and peptides; peptide mimetics; protein misfolding diseases; structure/function of membrane proteins, including integrins and viral ion channels; small molecule drug design; bioinorganic chemistry.

Abstract:

Not too long ago, the design of proteins from scratch that fold into predictable structures was considered an impossible task, but it is now increasingly routine. Given our ability to design protein structures the next challenge has been to design function. The success or failures of the designs informs our understanding of the principles underlying the desired function and additionally provides the first step towards design of proteins with useful functions not available to natural proteins. Some functions, such as binding to protein interfaces have been relatively easy, because the interactions that stabilize interfaces are also used to stabilize the folded structures of proteins, and available computational methods have been well calibrated to this task. It has been more difficult to design functions that involve molecular recognition of small, polar molecules or dynamic processes. I will describe methods for the design of proteins that bind small molecules, and the use of these proteins in potential biomedical applications such as drug delivery and as drug reversal agents.

A second challenging area of interest in *de novo* protein design has been the construction of useful membrane proteins. I will describe the design of semisynthetic membrane proteins that function as ion channels, and their application to DNA and RNA sequencing. The

talk will also demonstrate how *de novo* design can be used to test the mechanisms by which protons are conducted with high specificity and efficiency through transmembrane proton channels.



Bianxiao Cui, PhD
Professor, Stanford University



Integrin – Mediated Cell Adhesion and Its Linkage to Fibrosis

Dr. Bianxiao Cui is the Job and Gertrud Tamaki Professor of Chemistry and a fellow of the Wu Tsai Stanford Neuroscience Institute at Stanford University. She holds a PhD degree in chemistry from the University of Chicago and a BS degree from the University of Science and Technology of China. Dr. Cui develops new tools to study the nano-bio interface, membrane curvature, electrophysiology, and signal transduction in cells at normal and disease conditions. As a scientist and a teacher, she enjoys working with young scholars to explore the natural world with scientific innovations. Research in her group spans the disciplines of biophysics, cell biology, chemistry, material science, nanotechnology, and neurobiology. Her awards and distinctions include Ono Pharma Breakthrough Science Initiative award, Barany Award from the Biophysical Society, NIH New Innovator Award, NSF CAREER award, NSF Inspire award, Packard Fellowships in Science and Engineering, Hellman Scholar, Searle Scholar Award and Dreyfus New Faculty Award.

Abstract:

Membrane curvature in the range of tens to hundreds of nanometers is involved in many essential cellular processes. Membrane curvatures in living cells are often below optical resolution and are highly dynamics, making it a technical challenge to explore curvature-initiated signaling events. We use nanofabrication to engineer vertical nanostructures to precisely manipulate the location, degree, and sign (positive or negative) of the interface curvature in live cells. We found that these membrane curvatures drastically affect intracellular signaling on the plasma membrane. Very recently, we found that membrane curvature promotes the formation of a new type of integrin $\alpha V\beta 5$ -mediated cell adhesions – curved adhesions. Curved adhesions are molecularly distinct from focal adhesions and clathrin lattices and are prevalent in soft fiber matrices in 3D. These findings provide a mechanism of cell anchorage to soft protein fibers, which may serve as a therapeutic target for fibrotic diseases.



Phillip A Patten, PhD
Chief Scientific Officer,
Initial Therapeutics



DiCE Molecules – Lessons Learned from Revisiting an “Old Technology” & Taking a Non-raditional Approach to Financing and Exit

Phil Patten is chief scientific officer of ATP portfolio company Initial Therapeutics and an Entrepreneur in Residence at ATP, building on a career leading scientific innovation and discovery. Phil was a founder and CSO of DiCE Therapeutics, a publicly traded biotechnology company that used DNA-encoded libraries to discover and optimize oral inhibitors of challenging protein-protein interface targets. S011806, an oral inhibitor of IL-17A discovered at DiCE, is currently in clinical testing. DiCE was acquired by Eli Lilly in 2023. Before joining DiCE, Phil was at Pioneer Hi-Bred, where he was a DuPont Fellow and managed teams that utilized directed evolution and synthetic biology in agriculture. Prior to that, he was Sr. Vice President of Biology at Achaogen, where he led a team that discovered and brought forward the first clinical stage small molecule inhibitor of LpxC. Phil started his industrial career at Maxygen, where he applied directed evolution to therapeutic proteins and led a team that discovered an evolved type I interferon that was advanced to clinical studies in collaboration with Roche. He is an inventor of more than 90 granted US patents and has served on multiple scientific advisory boards. He served on the Biology and Bioengineering Chair's Council at Caltech from 2018-2023.

Phil earned a BS in biology from Caltech, a PhD in biological sciences from Stanford University and completed postdoctoral studies in chemistry at UC Berkeley.

Abstract:

DiCE Molecules was founded in 2013 to discover orally bioavailable small molecules to displace highly validated, multibillion dollar antibody franchises, with the expectation that there would be a large value inflection after demonstrating early clinical proof of concept. The technical approach was to in-license and industrialize the DNA encoded library technology and IP from the Harbury lab at Stanford and bet that this technology, augmented by traditional medchem, could deliver solutions to this technically challenging problem. The founders of DiCE chose in 2013 to take a non-traditional approach to financing by first raising a modest angel round and hiring a small team (~10), with the intent to secure partnerships with Pharma to support the company beyond the

angel round. Two such partnerships were obtained – with Sanofi and Genentech. A wholly-DiCE-owned clinical candidate was discovered using the intended technical approach and clinical proof-of-concept was demonstrated in 2022/23, triggering a subsequent acquisition by Lilly. Some of the lessons learned along the way will be shared.



Dinesh Patel, PhD
President and CEO,
Protagonist Therapeutics



Converging Biotech Innovation into Pharma Partnership: The Science and Art of Oral Peptide Therapeutics

Dr. Patel has served as a member of the board of directors and as the President and CEO of Protagonist since December 2008. He has 38 years of executive, entrepreneurial, and scientific experience that span the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining Protagonist Therapeutics, Dr. Patel served from 2006 to 2008 as the President and CEO of Arête Therapeutics, a privately held company focused on novel drugs for metabolic syndrome. Previously, he was the CEO and Co-founder of Miikana Therapeutics, an oncology based company, from 2003 until acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron) from 1996 to 2003, most recently as Sr. Vice President of Drug Discovery and Licensing. Vicuron research and development efforts led to two marketed drugs, anidulafungin (Eraxis®), and Dalbavancin (Dalvance®), and the Company was acquired by Pfizer in 2005 in a \$1.9 billion cash transaction. From 1993 to 1996, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax. Dr. Patel was a medicinal chemist at Bristol-Myers Squibb from 1985 to 1993. Dr. Patel received his PhD in Chemistry from Rutgers University, New Jersey and his BS in industrial chemistry from S. P. University, Vallabh Vidyanagar, India.

Abstract:

Oral peptides are the holy grail in the field of peptide-based drug discovery and development. Protagonist Therapeutics embarked on a journey of discovering and developing oral peptides effective against validated biological pathways that are currently targeted through multibillion-dollar blockbuster category of injectable antibody drugs. JNJ-2113 (formerly PN-235) is a first- and only-in-class oral IL-23 receptor antagonist for immunomodulatory diseases that is being jointly developed by JNJ and Protagonist through a partnership initiated in

2017. This talk will focus on Protagonist's decade long journey with the IL-23R program starting with the *de novo* discovery and design of oral peptides, partnership with JNJ, nomination of JNJ-2113, and positive results from a Ph2b psoriasis study (NCT05223868), leading ultimately to the decision to initiate a Ph3 registrational study in psoriasis.



Cheng Liu, PhD
 Founder, President & CEO,
 Eureka Therapeutics
 President of CABS (2005-2006)



Treating Solid Tumors with ARTEMIS T Cells Engineered with Antibody T – Cell Receptor (AbTCR)

Dr. Cheng Liu is the Founder, President and CEO of Eureka Therapeutics. Prior to founding Eureka, he was a Principal Scientist in antibody drug discovery at Chiron (now Novartis).

With over 20 years of experience in the field, Dr. Liu holds more than 500 patents and published patent applications of which over 100 patents have been issued worldwide and has authored numerous peer-reviewed papers on cancer immunotherapy.

Dr. Liu is the inventor of multiple first-in-class, clinical-stage cancer drugs against various tumor targets, including drugs targeting CSF1 for the treatment of bone metastasis, BCMA for multiple myeloma, and AFP and GPC3 for liver cancer. In 2007, he was awarded Special U.S. Congressional Recognition for his contributions to improving human health.

Dr. Liu is the editor of the book "Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development". Dr. Liu received his BS in cell biology and genetics from Peking University and a PhD in molecular cell biology from UC Berkeley.

Abstract:

- Designing ARTEMIS Antibody TCR (AbTCR) T cells to address the major hurdles in treating solid tumor
- Infiltrating into solid tumor under immunosuppressive microenvironment
- Targeting Alpha-fetoprotein (AFP) and Glypican 3 (GPC3) in advanced hepatocellular carcinoma (HCC)
- Demonstrating superior safety and efficacy profile of ARTEMIS T cells

Investment Panel Speakers



Moderator

Ella Li, PhD
 Founder & CEO, H7 BioCapital
 CABS Executive Council



Ella Li is the founder and CEO of H7 BioCapital, which is a venture platform that supports the transformational growth of healthcare companies through its venture, accelerator and community arms. She is also a venture partner of Network VC, focusing on seed to series A investment in the healthcare sector. She previously served as the CEO of Hanhai BioLabs, leading the team in life science investment. She was also the former CEO of ZGC Capital and the partner of its U.S. funds. She has also founded M7 Accelerator. She has established and managed several VC and fund of funds, including one with portfolio funds such as KPCB, Menlo, Andreessen Horowitz, Accel, Foundation Capital, and IVP.

Dr. Li has over 10 years of experience in biotech research and has rich experiences in therapeutic investment opportunities from discovery and clinical proof-of-concept to commercialization. Dr. Li earned her BS and MS degrees from Peking University, and her PhD from the University of Texas Health Science Centers. She completed her postdoctoral fellowship from Harvard Medical School. Dr. Li has extensive publications in prestigious journals with IMF over 10 including *Nature Communication*, *Cell Metabolism*, *Journal of Clinical Investigation*, *PNAS*, *Molecular Cell*, and *Diabetes*.



Ronjon Nag, PhD

Founder and President, R42 Group;
 Adjunct Professor, Stanford University



Ronjon Nag has been building AI systems for 40 years and sold companies he co-founded or advised to Motorola, RIM/Blackberry and Apple. He became a Stanford Interdisciplinary Distinguished Careers Institute Fellow in 2016, and teaches Longevity Science, AI, Genes and Ethics in the Stanford School of Medicine. He received a PhD from Cambridge, an

MS from MIT, the IET Mountbatten Medal, the \$1 million Verizon Powerful Answers Award, and the 2021 IEEE-SCV Outstanding Engineer Award. He is a cofounder and part owner of some 100 AI and biotech startups.



Ted Hou, PhD
 Founding Partner
 Berkeley Catalyst Fund



Ted is the founding partner of Berkeley Catalyst Fund, with the sector focus in life sciences (therapeutics, diagnostics, medical devices), biotechnology, agriculture and others. Ted started his career in the fiber optic communications industry. For over ten years he managed product marketing and product development and later served as the general manager of the passive component business unit for JDS Uniphase. Ted grew up in China, is fluent in Mandarin, and received his BS in chemistry from the University of Science and Technology of China in 1989. He received his PhD in physical chemistry from UC Berkeley in 1995, under the guidance of Nobel laureate Professor Yuan T. Lee. He was engaged for four years at the IBM Almaden Research Center as a postdoctoral research fellow.



Michael Ryan, MHA, FACHE FACHT
 Chairman & Managing Partner,
 EIG/MGR Capitalcal



Michael "Mike" Ryan is Managing Partner, MGR Capital and Chairman, Executive Impact Group (EIG) based in San Francisco. EIG has served clients from early stage startups to Fortune 50 companies in biotech, technology and life sciences including Proteolix (Amgen), Compugen, Healthcare.com, Drugstore.com (Walgreens), Novartis, Takeda and Lonza. He is a serial entrepreneur, CEO, investor, and global advisor with 40 years serving on 75+ boards of directors member on five continents. Mike in a former hospital, health system, digital health and technology CEO within the largest health systems in the United States including Ascension, Hospital Corporation of America (HCA) and HealthTrust. He is a CEO Advisor to 13 unicorns with \$187 billion in market cap and serves an advisor to seven venture funds. Mike has served as a lecturer, mentor

and judge at numerous universities including GWU, Tulane, UCSF. He has served as chairman of an ethics commitment and served on the NIH BioMedical Committee in Bethesda, MD.

He is a former White House Intern during President Jimmy Carter administration. He has a master in health services administration from the School of Business at The George Washington University and dual degrees from Regis University in international relations and communications.



Tao Fu, MBA
 CEO, Attovia Therapeutics
 Venture Partner, Frazier Life Sciences



Tao is currently the founder and CEO of Attovia Therapeutics, a biotech company focusing on developing small format biologics for immunology and cancer. He is also a Venture Partner at Frazier Life Sciences and joined Frazier in 2022. Tao has over 25 years of business development, general management, operations, strategy, and commercial leadership experience in the pharmaceutical and biotech industry.

Prior to Frazier, Tao served as President & Chief Operating Officer for Zai Lab, a publicly traded biotech company listed on both NASDAQ (ZLAB) and Hong Kong. He joined Zai Lab in 2018, holding a broad set of responsibilities including strategy, operations, business development, CMC, quality, and other corporate functions. Previously from 2015 to 2018, Tao was Executive Vice President, Chief Commercial and Business Officer of Portola Pharmaceuticals (PTLA), a publicly traded biotech company specializing in cardiovascular disease and cancer. In this role, Tao led Portola's commercial operations, marketing, sales, and business development. From 2014 to 2015, Tao was Vice President, Head of M&A and Alliance Management at Bristol Myers-Squibb (BMS), leading the company's corporate development, alliance management and venture capital investing activities. Prior to BMS, Tao worked at Johnson & Johnson (J&J) for 11 years, holding a number of leadership positions with increasing responsibilities, most recently as Vice President, Head of M&A, responsible for J&J's global M&A activities in pharmaceuticals. Over his career, Tao oversaw and was the primary deal negotiator for over 50 high impact business development transactions. Earlier in his career, Tao worked at Scios and McKinsey & Company.

Tao received an MS in biology from the University of Rochester, and an MBA in finance and marketing from Vanderbilt University. He did his undergraduate studies in biology at Tsinghua University and is a Chartered Financial Analyst (CFA).

AI Panel Speakers



Moderator

Cheni Kwok, PhD, CLP
Managing Partner & Founder,
Linear Dreams LLC
President of CABS (2016-2017)



Dr. Cheni Kwok is a senior biopharmaceutical executive with broad operational expertise. She has executed over 200 transactions including mergers and acquisitions, partnerships, licensing, divestitures, spin-offs and project financing. Dr. Kwok is the Managing Partner and Founder of Linear Dreams LLC, a management consultancy for the life sciences industry. Linear Dreams was established in 2011 and based in the San Francisco Bay Area. The firm's engagements include a broad range of business and corporate development activities for 69 biopharmaceuticals companies, contract research & non-profit organizations, research institutes and investors in USA, Europe, China, Taiwan, Korea and Singapore. Prior to founding Linear Dreams, Dr. Kwok served as Sr. Vice President, Corporate Development at Poniard Pharmaceuticals, Director of Business Development at Celera Genomics, Associate Director of Business Development at Exelixis, and in various research management, technology assessment and alliance management roles at SmithKline Beecham plc (now GlaxoSmithKline plc). Dr. Kwok received a bachelor's degree with first class honors in biotechnology from Imperial College London, UK, a PhD in human molecular genetics from the University of Cambridge, UK and has earned the Certified Licensing Professional credential. Dr. Kwok is serving on the Board of Directors of the CABS,



Pek Lum, PhD
Founder and CEO, Auransa Inc



Pek is co-founder and CEO of Auransa, a clinical-stage, AI-native biopharma advancing therapies for cancer and cancer-related diseases. An early pioneer of genomics technology, Pek was an early team member of Rosetta, a microarray technology company, which was later acquired

by Merck. At Merck, Pek championed the integration of data science into traditional biological discovery, helping to advance the company's development pipeline. After Merck, Pek served as Chief Data Scientist of Ayasdi, an AI software company, before co-founding Auransa in 2014.

Throughout her career Pek has advised several startups at the intersection of biopharma and massive data, including Resolution Bioscience, as well as the Michael J. Fox Foundation for Parkinson's Research. Pek holds a BS from Hokkaido University in biochemistry and received her PhD studying molecular genetics at the University of Washington. Her research, widely published in scientific and medical journals such as *Nature* and *Cell*, has helped to advance drug discoveries and our understanding of complex disease.



Stephanie Sharron, JD
Partner Morrison & Foerster LLP



Stephanie is a trusted advisor to companies with technology and life sciences transactions, representing both private and public companies, from emerging growth through the Fortune 50. Stephanie focuses on helping companies that leverage data through technology in structuring their business and commercial transactions.

Stephanie has over two decades of experience working with clients on the complex technology, IP, and data rights issues across technology and business sectors, with a focus on artificial intelligence, including: pharmaceuticals, diagnostics, medical devices, healthcare, and digital health, among others.

Stephanie serves on the Responsible AI Venture Council, part of the recently launched Lucas Institute for Venture Ethics at Santa Clara University's Markkula Center for Applied Ethics. Stephanie is also a member of the firm's global Environmental, Social, and Governance steering committee.

In addition to publishing on a variety of legal topics related to AI, since 2016, Stephanie has taught as a guest lecturer on data licensing and other IP-related topics in Cornell Law School's Technology and Entrepreneurship LLM program at CornellTech.



Nicolas Tilmans, PhD
Founder and CEO, Anagenex



Nicolas has a long history of straddling the line between computational and bench science having earned degrees in computer science but also a PhD on directed evolution using DNA encoded libraries (DELs). He has also built and led machine learning engineering teams. He launched Anagenex to accelerate drug discovery by combining DELs and machine learning to rapidly explore chemical space. Nicolas possesses a diverse academic background that seamlessly bridges the realms of computational and bench science. With a bachelor's degree in computer science and another bachelor's degree in biochemistry from the University of Maryland, he established a solid foundation in both fields. Furthermore, he pursued a PhD in biochemistry at Stanford, focusing on the intricate domain of directed evolution using DELs.

Career Panel Speakers



Moderator

Jen Majeti, PhD, MBA
Board member, BeyondSpring
President of CABS (2015-2016)



Dr. Majeti is an investor, biotech company advisor, and executive with over twenty years of experience in the biotech and pharmaceutical industry. She carried out diverse roles with increasing responsibilities in biotech and large multinational companies, encompassing cross-functional experiences in R&D, business development, supplier management, and outsourcing in the biopharmaceutical industry. She is currently a board member of BeyondSpring. She is also serving as an advisory board member of Healthcare and Innovation Design at the school of engineering at Santa Clara University. Most recently she was the Head of Global Collaborations of Erasca. Prior to that, she was Global Category Leader for Roche External Alliance, Sr. Director of Business Development for BioDuro, and Sr. Scientist at Amgen and GPC Biotech.

Dr. Majeti is the past president (2015-2016) and currently a member of board of directors of the CABS. She is also a member of the BayHelix Group.

Her PhD in molecular genetics was from the University of Wisconsin at Madison, and she obtained her postdoctoral training at the Howard Hughes Medical Institute at UCSF. She also earned an MBA degree from the Leavey School of Business at Santa Clara University, graduating as a member of the Beta Gamma Sigma Honor Society. She completed her undergraduate studies in biochemistry at Fudan University in China.



Jing-Shan "Jennifer" Hu, PhD
Former Sr. Advisor & Founding
Partner of Qiming U.S.
Healthcare Fund
President of CABS (2006-2007)



Dr. Hu has worked in venture investment on innovative therapeutics in the U.S. since early 2016 as Sr. Advisor, Partner, or Venture Partner for investment firms including Qiming U.S. Healthcare Fund. Her investment successes at Qiming U.S. include leading series C1 financing of AMRO Biosciences (acquired by Eli Lilly for \$1.6B), contributing to investment in Cadent Therapeutics (acquired by Novartis), as well as Kezar Life Sciences and Ventyx Biosciences with successful IPOs on NASDAQ.

Prior to joining healthcare investment, she had worked in partnering/licensing, business development, R&D at three multinational pharmaceutical companies and two biotech companies in the U.S. with various roles, including VP and Head of (External) Innovation Center China at Bayer Pharmaceuticals, Director of Licensing & External Research at Merck & Co (MSD), Head of Functional Biology at Roche Palo Alto, Program Manager of Pharmacogenomics at Affymetrix, and Scientist of Protein Therapeutics at Human Genome Sciences.

Dr. Hu obtained her post-doctoral training at Harvard Medical School, a PhD from University of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center, and a BS degree in biochemistry from Peking University.



Shichang Miao, PhD
Managing Partner,
Rivermount Fund
President of CABS (2009-2010)



Dr. Shichang Miao is a seasoned drug developer with 25+ years of experience in drug discovery and development through three biotech companies (Tularik, ChemoCentryx and Amgen). He spent 15 years working at ChemoCentryx, where as VP for preclinical development and clinical pharmacology, he and his team played a pivotal role in the discovery, development and NDA approval of Tavneos™ (avacopan), a complement C5a receptor antagonist indicated for the treatment of a rare autoimmune disease. He has been a partner of Rivermount Fund which specializes in early-stage investment in healthcare startup companies. He has been serving on the advisory committee of the Stanford SPARK Translational Research Program and the Bio Committee of Life Science Angels, a prominent angel investment group focusing on healthcare startups. He has been an active contributor to biotech professional societies, as the founder and president of Pharmaceutical & BioScience Society (PBSS) and a former president (2009-2010) of CABS. He obtained his PhD in organic chemistry and postdoctoral training in biochemistry at the University of British Columbia in Vancouver, Canada.



Janet Xiao, PhD, JD
Partner, Morrison & Foerster LLP
President of CABS (2011-2012)



Janet Xiao, PhD focuses her practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Janet's clients range from large multinational biopharmaceutical companies, such as Celgene and Genentech, to emerging startup companies around the world. She advises her clients on patent matters relating to various technologies, including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals. She works extensively in performing IP due diligence reviews in the contexts of VC investments,

technology transactions, mergers and acquisitions, and marketing and manufacturing clearance for biopharmaceutical products.

Recognized by Chambers as being highly sought after for patent prosecution and strategy mandates by innovators from around the world, Janet develops and strengthens her clients' complex patent portfolios to maximize their commercial value. She is instrumental in developing strategies for multibillion-dollar patent portfolios for pharmaceutical clients. As impressed clients noted to Chambers, "Janet's work is thorough, polished and always of the highest caliber. She is well equipped to advise international clients on patent prosecution and strategy in the biotech industry, drawing on substantial technical knowledge."

Janet is the Head of firm's China Life Sciences Group and served as co-chair of the global Life Sciences Group from 2016 to 2019. She is among the very few IP attorneys in the world who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China and Chinese clients, and she has been the go-to counsel for IP issues in U.S./China cross-border transactions and operations in China. Since 2005, Janet has been actively involved in the leadership team of the CABS, a nonprofit organization dedicated to bridging the life sciences communities in the U.S. and China, including serving as president for the 2011-2012 term.



Zhonghua Pei, PhD
Senior Vice President, Neuron23
President of CABS (2013-2014)



Dr. Zhonghua Pei serves as Sr. Vice President of Chemistry at Neuron23. Zhonghua has rich and extensive drug discovery experience in oncology, inflammatory diseases, metabolic disease (diabetes & obesity) and neuroinflammatory diseases. Zhonghua started his industrial career at Abbott Laboratories, then joined Genentech in 2007 and later Ideaya Biosciences in 2017. Over a period of more than 20 years he has made significant impact and contributions to the discovery of multiple drug development candidates at Abbott, Genentech and Ideaya, either as an individual contributor or as a team leader. He has authored or co-authored more than 45 peer-reviewed papers, reviews and book chapters and over 40 patents.

Zhonghua obtained his BS degree from University of Science and Technology in China, MS degree from Rensselaer Polytech Institute and his PhD in chemistry from MIT. Zhonghua is the past president (2013-2014) and currently a member of board of directors of the CABS.



Alex J. Zhang, PhD, MBA
Founder & CEO
OneTwenty Therapeutics
President of CABS (2017-2018)



Dr. Zhang is the Founder and CEO of OneTwentyTherapeutics, a clinical stage iPSC-based cell therapy company. He was the Chief Scientist of Hanhai Holdings Group, and the CEO of Hanhai Silicon Valley, an early-stage investor and cross-border incubator for life sciences and frontier tech startups based in San Francisco Bay Area. Prior to Hanhai, Alex was the Co-founder and Managing Partner of Enverest, LLC., a Silicon Valley based innovation solutions and investment advisory firm, with branch offices in China and Singapore. Prior to founding Enverest, Dr. Zhang spent over four years at Thermo Fisher Scientific, where he held several senior business roles. From 2001 to 2009, Dr. Zhang was a Sr.Scientist at Tularik (acquired by Amgen in 2004), where he led drug discovery endeavors in oncology, cardiovascular and metabolic diseases therapeutic areas. Over the past decade, Dr. Zhang has been advising a number of successful biotech, MedTech and digital health startups and venture capital firms.

Dr. Zhang is currently a Board Member of the CABS. He served a number of leadership roles in the Executive Council of CABS, including as the President in 2017-18. Dr. Zhang earned MBA degree at Cornell University, PhD in organic and analytical chemistry at Texas A&M University, and BS in chemistry at Shandong University. His research has led to the publication of 17 peer reviewed articles and 4 patents.

Closing Remarks Speaker



Keting Chu, MD, PhD
Founder, CEO, and Chairman of
the Board, Bluejay Therapeutics
President of CABS (1998-1999)



Dr. Keting Chu is an experienced biotech executive, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture investments.

Prior to founding Bluejay, Keting was a Partner and a Venture partner at LYFE Capital. Working with the team in Lyfe capital, Keting helped to close \$550M Lyfe Capital Fund III and invested in Ansun Biopharm, Pliant Therapeutics and Tempest Therapeutics. Pliant and Tempest went IPO in NASDAQ successfully in 2020 and 2021. Keting was a venture partner in Apple Tree Partners briefly. Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS). There she was responsible for venture philanthropy, also known as the Therapy Acceleration program. At LLS, Keting led the investment into Celator, Stemline, Constellation, Affirmed, ArgenX, Kite Pharma, Kiadis, OncoPep, Valor and a number of projects in academic institutions with the focus on proof-of-concept (POC) studies in patients. Three of the nine companies received "Break-through" designation by the FDA in 2016 after positive POC studies. Celator was acquired by Jazz Pharma for \$1.5B, Kite by Gilead for \$12B and Stemline by Menarini for \$677M. Three NDAs, by Celator, Kite and Stemline, were approved by the US FDA successfully. Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB and BioCubed Corporation. For her first startup company, Five Prime Therapeutics, Keting was Vice President of Biology and Head of R&D where she built the R&D strategy and team, established the technology platform and generated a product pipeline. Prior to Five Prime, Keting was the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical and clinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases. Three cancer therapeutic antibodies that Keting led from discovery to phase I clinical trials went through phase II and III clinical testing.

Keting earned her MD specialized in infectious diseases in Sun Yat-sen Medical University in China, and PhD in microbiology and immunology at UCSF. She also conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.

Diamond Sponsor Speaker



Wei Huang, MS
President of Henlius,
Chairman of Aton Biotech



Pharmaron's integrated IND-enabling service platform and cultivating global partnerships. A proud alumna of Peking University, she earned her BS in cell biology and genetics before pursuing a PhD in pathology at Birmingham. Liyu spent many years in cancer metabolism research at the UCSF before transitioning to the biotech industry. She has carved out a career in business development with biotech firms, CROs and CDMOs such as Abcam, WuXi AppTec, Ji Xing Pharmaceuticals and Pharmaron. In these roles, she nurtured enduring relationships and spearheaded successful global alliances. A recent graduate with an MBA from the Leavey School of Business, Santa Clara University, Liyu is passionately dedicated to advancing drug discovery and development by forging meaningful connections and optimally utilizing global scientific resources.

Considerations and Case Study on Drug Development and Commercialization

As the President of the company, Wei leads the manufacturing, quality, MSAT, clinical supply, engineering, supply chain and other operations functions. Wei holds a bachelor degree in biochemical engineering from East China University of Science and Technology and a master degree in chemical and biochemical engineering from the University of Maryland. Before joining Henlius, Wei held several senior management and leadership positions in the pharmaceutical and biotechnology industry. She has over twenty-five years experience in process development, technology transfer, manufacturing, GMP facility design, and quality system implementation.

Abstract:

- Drug development process overview
- CMC activities and considerations from clinical to commercial
- Case study: Strategies for accelerated submission of multiple molecules

Lunch & Learn Session Speakers



Liyu Wu, PhD, MBA
Sr. Director of Business
Development, Pharmaron



Empowering Drug Discovery and Development with Pharmaron's Global Integrated Offering: Quality, Speed, Flexibility, One-Stop Solution

Dr. Liyu Wu is currently a Sr. Director of Business Development at Pharmaron, where she plays a pivotal role in formulating business strategies for



Bill Glencross
Director of Sales, Mispro



Contract Vivarium Facilities: Biotech's Fastest Emerging Option for Preclinical Animal Studies

Bill leads Mispro's national sales team supporting the company's network of full-service contract vivarium facilities. With locations in all major US biotech hubs, including in South San Francisco and Palo Alto, Mispro offers biosciences companies of all sizes access to turnkey animal research infrastructure for preclinical R&D, which includes vivarium space, veterinary oversight, animal husbandry, and IACUC.



Yifu Liu
Executive Director, JLLake



How JLLake Could Help Cross-Border Entrepreneurs

Yifu Liu is the Executive Director at JLLake, a prominent U.S.-China cross-border accelerator backed by Oriza Holdings, a leading deep-tech investment institution in China. He has successfully built JLLake from

scratch, and has earned the reputation by providing collectively \$500 million worth of entrepreneurship resources to startup founders. As of 2023, JLLake's cross-border accelerator Pioneer program has attracted over 400 startup applicants, and 98 of them received the offer within the program. Prior to his role at JLLake, Yifu Liu served as the co-founder and Business Development Head at SVC Venture Club (Merged with HYSTA in 2017), pioneering building U.S.-China investor networks. Yifu previously received his Master degree in Finance.



Jiyong Zhang, PhD
Head of Business Development,
Nona Biosciences



Building Next – Gen Biologics Leveraging Industry-Leading Fully Human Heavy Chain Only Antibody Platform

Nona Biosciences is a global biotech technology focusing on innovation of antibody therapy. Jiyong has 10+ years' experience in therapeutic antibody research and bispecific antibody engineering. Jiyong received his PhD in pharmacology from Okayama University, Japan, and completed his postdoc training at Brown University. Prior to joining Nona, Jiyong has worked at Alexion and Abbvie focusing on antibody discovery, engineering, and bispecific antibody R&D.



Karen Han, PhD
Field-based Account Manager,
GenScript



GenScript's One – Stop Solution Takes Your Research to the Next-Level

Karen Han is a Field-based Account Manager within the North American Sales & Tech Support at GenScript. Prior to her role at GenScript, Karen held a significant position at a stem cell therapeutic company, where she excelled in ensuring the production of clinical-grade stem cells ad-

hering to cGMP standards. In addition to her responsibilities in stem cell manufacturing, she played a key role in developing Standard Operating Procedures for stem cell phenotyping assays and functional assays, contributing to the company's research capabilities. During her doctoral studies, Karen's research focused on developing innovative immune cell therapies responsive to mechano-environmental cues in the context of cancer metastasis.

Karen holds a PhD degree of pharmaceutical sciences from University of California, Irvine and an MS in pharmaceutical sciences from University of Southern California, Los Angeles.



Yujiao Zhang, PhD
Product Marketing Scientist,
Kactus



First-to – Market Recombinant Proteins & Enzymes for Tomorrow's Biopharma & Diagnostic Innovations

Yujiao Zhang has been living in Paris for 13 years. She completed her PhD in immunology from the University of Paris where she led a preclinical project on the role of an immune-related protein in atherosclerosis. Yujiao is proud to have recently published her findings as the first author in *Nature Communications*.

After completing her PhD, Yujiao worked at BGI Genomics as an account manager where her responsibilities included establishing and nurturing professional relationships, managing intricate NGS projects, and maintaining robust communication with her French clientele.

Currently, Yujiao is excited to be a part of KACTUS as a Product Marketing Scientist, utilizing her diverse background and scientific communication skills to contribute to the organization.

2022-2023 Selected CABS Activities

2022 BioPacific Conference



sponsors, attendees, organizing committee members and volunteers.

The theme of the Conference was "Resilience and Ingenuity: Embracing Opportunities in a New Normal." The conference included 3 keynote talks, 1 K.

The 2022 Biopacific Conference, also known as the 23rd Annual Conference of CABS, was held on November 12th, 2022 at San Mateo Marriott San Francisco Airport, California. As our first in-person conference since the COVID-19 pandemic, it had 42 distinguished speakers/panelists/moderators, 51 sponsors, and attracted more than 600 attendees. The amazing success would have not been possible without the contributions and participation of all the speakers,

Fong Award speech, 1 fireside chat, 4 scientific speeches, 5 panel discussions, and 9 breakout room presentations, all by industry and academic leaders. These exciting talks and panels were grouped into 2 morning sessions, 2 noon sessions, 2 afternoon sessions, and the inaugural China Night session.

To commence the Conference, Dr. Kate You, President-Elect of CABS and Organizing Committee Chair of the

Conference, gave warm welcome remarks and an overview of the agenda. Dr. Carrie Wang, President of CABS, then gave the State of the Society speech, highlighting the activities, growth, and achievements of CABS in the past year.



Morning Session 1 (Chair: Dr. Hesong Sun)

Dr. Dan Sutherlin, Sr. Vice President of Small Molecule Drug Discovery at Genentech, presented the first keynote speech. He first discussed the challenges in drug discovery, then went on with three vignettes to delineate some of Genentech's approaches to tackle the challenges. Dr. Yibin Kang, professor at Princeton University, described a new class of cancer fitness genes that are critical for cancer metastasis but not for normal tissues.

Following the two exciting talks, Dr. Kenneth Fong presented the 2022 CABS K. Fong Award to Dr. Scott Liu, founder and CEO of HanchorBio, Co-Founder and former CEO of Henlius.

In his acceptance speech, Dr. Scott Liu discussed how HanchorBio achieved the goal of simultaneous targeting with its novel Fc-Based Designer Biologics (FBDB™) platform.



Morning Session 2 (Chair: Dr. Guanghui Han)

The Fireside Chat within the session was moderated by Dr. Kenneth Fong with two outstanding entrepreneurs, Drs. J. Jean Cui and Yishan (Peter) Li, the Co-Founders of Turning Point Therapeutics. They talked about how the company got started, the key ingredients for its



success, and shared their experiences with the audience. Dr. Kenneth Fong's moderation was full of humor, and the entire Fireside Chat was joyous.

The following panel discussion, with Dr. Ella Li as moderator, and Drs. Orrin Ailloni-Charas, Cheni Kwok, and Mr. Neil Littman as panelists, discussed the healthcare innovations from the perspective of investors and strategists.

Noon Sessions (Chairs: Drs. Yanan Wang and Vivian Liu)

The two parallel noon sessions consisted of 9 lectures that showcased better tools and approaches - from manufacturing to patients' ends - for drug discovery. The noon session speakers are Dr. Yangzhou Wang, CEO of Porton Advanced Solutions; Dr. Connie Sun, SVP and Global Head of BD, Small Molecules at Pharmaron; Mr. Charles Li, VP of BD at Pharmaron; Tracy Zhao, Sr. Scientist at ACROBiosystems; Dr. Xiaoxi Wei, co-founder and CEO of X-Therma; Min Park, Chief Business Officer at Aton Biotech; Dr. Michael Zhao, Q Bay Boston Partner; Linda Zhou and Thomas

Anderton, Partners of K&L Gates; Ilean Chai, Associate Director of BD at Biontius.

Afternoon Session 1 (Chair: Dr. Zhiyong Yang)

This session consisted of two talks and one panel discussion. Dr. Yifan Cheng, a member of National Academy of Sciences and American Academy of Arts and Sciences, an HHMI investigator, and a professor at UCSF, opened the session with his keynote speech titled "Structural Biology in the Era of Single Particle Cryo-EM." Next, Dr. Jennifer Allen, Executive Director of Research at Amgen, gave a talk titled "A Day in the Life of a Medicinal Chemist - Discovery of Sotorasib." This session ended with a panel discussion with Dr. Yan Wang as moderator, and Drs. James Jin, Ray Chen, and Mr. Yifu Liu as panelists. The panel gave an in-depth discussion on the role of incubator/CRO in the drug discovery process.

Afternoon Session 2 (Chair: Dr. Xi Fang)

Starting this session, Dr. Anjali Shukla, Lead of FDA Emerging Technology Team, introduced the FDA Emerging Technology Program. Dr. Amit Mehta, Vice President and the Head of BD at Genentech, provided an overview of Genentech's approach to evaluate external innovation, strategic focus areas, and recent partnerships. The panel discussion "AI in Pharma and Life Science" of this session was joined with 3 global experts, Drs. Yang Shao, Abraham Heifets, and Michelle Chen, who discussed applying AI to innovations in pharma and life sciences.

The day program ended with closing remarks by Dr. Jessica Sun, Vice Chair of the Organizing Committee of the 2022 Biopacific Conference. Her remark "Today we are all volunteers!" resonated with the audience with a big round of applause.



China Night

This program is special at least in two-fold: first, it was the first night session in the history of the Conference; second, it was the first time the Conference had trans-Pacific parallel sessions connected by internet. The program was the result of the close partnership among CABS, Fosun Pharma USA, BayHelix, and Hanhai BioLabs. China Night included one keynote speech and one panel discussion in Shanghai, and another panel discussion in San Mateo. The night program began with the welcome remarks by Mr. Deyong Wen, CEO of Fosun Pharmaceutical; and Dr. Carrie Wang, President of CABS.

During the keynote talk, Mr. Yuanyuan Qi, COO of Fosun Kite, shared the history of his company, and Fosun Kite's successful business strategy to make the first commercialization of a cell therapy product in China.

The first panel discussion (in Shanghai), with Dr. Wei Wu as moderator, and Drs. Guoliang Yu, Jinfu Yang, Dajun Yang, and Jun Zhu as panelists, had an insightful sharing on accelerating globalization by expanding the Chinese Biopharma Innovative Ecosystem. The second panel (in San Mateo), moderated by Dr. Alex Zhang and joined by panelists Drs. David Shen,

George Wu, Dandan Dong, and Janice Zang, had an insightful discussion on the innovations of US-based biotechs and new developments in therapeutics.

To conclude, we would like to express our humble gratitude again to all speak-

ers, sponsors, attendees, organizing committee and volunteers. It was your unwavering support and unquenchable passion for CABS and the biopharmaceutical community that rendered great success to the Conference. We look forward to seeing you in future events.



2023 CABS Investor Forum



The 2023 CABS Investor forum was successfully held on January 11, 2023, during the 2023 JP Morgan Healthcare Conference Week. The Forum was held in a hybrid format. In-person event was held in MOFO SF office with 80+ attendees and there were 100+ people joined by Zoom.

The Forum consisted two panel discussions. The first panel was moderated by Janet Xiao, Partner, Morrison Foerster, and its theme was "Trends, Opportunities and Outlook for Biotech Investment." The five panelists were Christian Grondahl, a veteran entrepreneur; Jim Krenn, Partner of Morrison Foerster; Arthur Kuan, CEO of CG Oncology; Cheni Kwok, a very experienced consultant; and Sean Kendall, an investor from ARCH.

The 2nd panel was moderated by Alex

J. Zhang, Managing Director, Lifespan BioLabs, and its theme was "Growing Opportunities and Strategies for Biopharma Companies in a Changing World." The panel also had five panelists: John Adamou, CBO from CSPC Pharmaceutical Group; Oliver Kong, CMO from IASO Biotherapeutics; Neela Patel, CBO from Bonum Therapeutics; and Eugene Wang, CEO from Help Therapeutics; and Allen Jiang, CBO from Xtalpi.



2023 CABS EC transition meeting



Chinese American Bio/Pharmaceutical Society (CABS) has been founded for 24 years. The term of its Executive Council (EC) is usually one year. Each year CABS holds a transition meeting, at which the President-Elect assumes the presidency from the immediate former President, a new President-Elect becomes the chair of the BioPacific Conference, and a new EC under the leadership of the President and President-Elect is formed.


This year's CABS EC transition meeting was held on February 11, 2023 in Foster City. Members of the 2022 EC and the 2023 EC attended the meeting.

At the beginning of the meeting, Dr. Carrie Wang, the immediate former CABS president, summarized the 2022-2023 achievements, including but not limited to the 2022 BioPacific Conference, 2023 Investor Forum, 2023 Chinese New Year Gala, etc.

On behalf of the Board of Directors of CABS, former CABS president Dr. Yang

Tian described the CABS bylaw and code of conduct to the audience.

Dr. Kate (Yuying) You, the new CABS President and Chair of 2022 BioPacific Conference, and Co-Chairs of all committees of the 2022 CABS EC reviewed the achievements and lessons in the past year, and shared their prospect for the corresponding committees in the coming year.



Plaques and/or award certificates were presented to awardees of 10-Year, 5-Year, Co-Chair, Outstanding EC, or Special Contribution Awards in the year of 2021 and 2022



Dr. Kate (Yuying) You, after assuming the presidency, then announced the members of the 2023 CABS EC.

Last but not least, Dr. Jessica Sun, the new President-Elect and Chair of the 2023 BioPacific Conference, gave a heads-up on how the new EC will be geared up to prepare for the 2023 BioPacific Conference.

back to the next generation, but also an opportunity for them to continue to learn from their mentees as well. There were many key takeaways and lessons.



Mentees ranged from early to late career stages to newly transitioned career paths. They were overjoyed to have been paired with mentors to guide them in their career growth, navigating strategically, and communicating successfully for the next phase of achieving their career goals. Many expressed interest in continuances of the program in 2023, some mentees were open to transition to be a mentor.



2023 Career Building Series: Strategically Mapping Your Career



2021-2022 CAN Program Graduation Ceremony



Since being established in 2010, the Career Advisory Network (CAN) Program has become one of the major annual events of CABS. CAN is a mentoring program hosted by the Career and Business

Development Committee (BCD) of CABS. It is a direct one-to-one pairing mentorship program to guide mentees in their career paths including business development, entrepreneurship, and scien-



tific career paths in both academia and industry. This is a free program for CABS members. The mentorship program is made successfully through hard work, dedication, persistence, and service of the mentors who in their busy schedules carve out time to guide the mentees.

On January 14, 2023, CABS celebrated the first (CAN) graduating class post COVID. The graduation opened with networking, followed by the sharing of reflections, experiences, and overall learning from both mentors and mentees.

Many mentors maintained that it was not only an opportunity for them to give

To kick off the year, on March 25, 2023, BCD held the first in-person workshop for a Career Building Series since the COVID lockdown. The event was a full house with over 50 attendees. The speaker Kay Tong, MA, Head of Quality System and Compliance, Sana Biotechnology opened with a presentation and provided tips, tricks, and tools for attendees to use to map their career. The focus was on the power of choice and to identify career goals matched with lifestyle goals.



This was followed by a fireside chat with Sarah Chen, MD, Clinical Research Medical Director, Amgen, and Yue Wang, PhD, Business Development Manager, Mission Bio. Both were mentees of Kay, who have used the career map to bring clarity to their career path.



The workshop moved to have attendees complete a career map from the tool provided as part of the workshop. The workshop closed with Q&A and a networking opportunity for all attendees.

2023 CAN Program Kick-Off Meeting



The kickoff meeting of the 2023 CABS CAN program took place on April 22, 2023, at Hanhai Silicon Valley Center. Fourteen mentors and 31 mentees attended the event.

Kay Tong, co-chair of BCD outlined the logistics of the program, the expectations for mentors and mentees. Kay also shared her thoughts on the importance of mentorship and how the CAN program can make a positive impact on both mentors and mentees.

Dr. Shichang Miao, a successful entrepreneur and mentor, shared his career story and mentoring experience, and provided invaluable advice, such as whether and when to join a big or a small company.



Overall, the kickoff meeting was an excellent start for this exciting CAN program, and attendees left with the feelings of empowered and motivated to achieve success. Special thanks to Jack Zhu and Dr. Xiaojie Chen, the coordinators of 2023 CAN program. We sincerely thank the exclusive sponsorship from Porton Advanced Solution, a cell and gene therapy CDMO company.



2023 Chinese New Year Gala

Before the COVID-19 pandemic, CABS held the Chinese New Year Gala every year to provide a platform for its members and their families and friends to celebrate and (re)connect. After two years of hiatus due to the pandemic, CABS is pleased to announce that it has resumed the tradition and successfully held its first Chinese New Year Gala post the COVID-19 pandemic. On February 4, 2023, more than 250 people gathered together at the Mountain View Senior Center to celebrate the beginning of the Year of Rabbit as the pandemic is gradually receding into the past.

Attendees were first greeted with spring couplets, red lanterns, Chinese character riddles and many other decorations that are particular to the Spring Festival tradition.



The attendees were then treated with delicious and authentic Chinese foods, and provided with ample opportunity to meet with new people and reconnect with old friends.

More than 100 performers delivered a dazzling program to the audience. We are greatly indebted to them, many of them performed for free.

Seven prizes in total were drawn in the intervals of the program. All prize winners responded on the first calls, attesting the attractiveness of the program. Pictured is a senior fan of CABS events, selected to draw the top prize, presenting it to a little girl, the lucky winner.

This Chinese New Year Gala was organized by the CABS Social Life Committee, led by co-chairs Li Wang and Michael Xie. Over 20 volunteers helped to make the Gala a huge success.

We would like to acknowledge the generous support of following sponsors: PharmaBlock Sciences (<https://www.pharmablock.com/>) New York Life Insurance (<https://www.newyorklife.com/>)



Dragon Boat Race at the Foster City Boat Park, on June 11, 2023

Hosted by the Social Life Committee (SLC) of CABS.



2023 CABS Summer BBQ at Boothbay Park, Foster City, on August 27, 2023

Hosted by the SLC of CABS.





Symposium on Contract Development and Manufacturing Organization (CDMO)

On June 3rd 2023, the Science & Technology Committee (STC) of CABS held a symposium named "Accelerating the Development and Manufacturing of Drugs of Various Modalities".



The in-person event was held in Hanhai Biolabs at Millbrae with more than 70 attendees. We invited four industry experts to share their experiences and opinions on the active pharmaceutical ingredients (APIs) manufacturing process, the technology and the process development of various drug modalities. The speakers are Ms. Wei Huang, COO & SVP from Shanghai Henlius Biotech; Dr. Jennifer Kuo, Sr. Director from Aton Bio; Dr. Xiaocen (Chris) Li, Supervisor from Axolabs; Dr. Matteo Villain, VP from Bachem Americas.

Ms. Huang started the symposium by giving an overview of CMC, followed by three captivating case studies on antibody manufacturing, providing real-world examples, illustrating the practical application of CMC principles and their impact on successful antibody manufacturing. The second speaker, Dr. Kuo ignited a sense of curiosity and anticipation among the audience, eager to explore the capabilities of this innovative CDMO and how it could positively impact their own drug development

programs. Next, Dr. Chen introduced oligonucleotide GMP manufacturing with details in each step of the process, and gave examples on how to troubleshoot the production process. Finally, Dr. Villain gave a short introduction to the history of BACHEM, then discussed the peptide manufacturing process and the regulations, and emphasized the importance of product quality and how it is controlled during GMP manufacturing.



This symposium is a continuation of STC's symposium on antibody-based drug CMC and CDMO last year. The current symposium offered rich information on the GMP manufacturing of antibodies, ADCs, oligonucleotides, and peptides.

This event was sponsored by Aton Bio.



Silicon Vally Innovation Seminar Series - Prospects and Future of Life Science Innovations

Hosted by the International Collaboration Committee (ICC) of CABS on May 16th 2023 (PDT).

	I-Corps bootstrapping	Post I-Corps acceleration	VC-created
Targets	Academic innovators	Top-tier I-Corps companies	Acquired technology
Guidance	Instructors, mentors	Mentors, advisors	VC internal team
Stage	PMF to prototyping	Business model validation	Development milestones
Capital	Self-financed	Non-dilutive funding	Equity
End goal	Complete I-Corps	Investment	Step-up in valuation

S. K. Marus, J.A. Blaho, Nature Biotechnology, 2023, 41, 134-135

7G BioVentures Team: Highly Experienced & Complementary
Vincent Xiang, PhD, MBA -- Managing Partner
 20+ year experience investing and operating in global life science industry

Professional Background:

- Willmore Capital Partner
- 8 Dimensions Capital
- BayR Life Science VC
- Franklin Templeton Inc. BioAdvance

Head of BioVenture Partner
 Managing Director
 Portfolio Manager/Analyst
 Life science Angel investing

Standard Spark Program:

- Humantec HC Group
- LDK Prognosis
- BayHelix
- Arcadia Research Corp
- SinoPharm

Advisor:

- Head of Global Investments
- Co-Founder, Board Director
- Founding member
- Director, VC investments
- Researcher

Education:

- 35 scientific publications, 3 patents, member of scientific and executive networks
- Wharton MBA, Sony Brask University PhD, Fudan University BS

Webinar: Accelerating Drug Discovery & Disease Treatment Through Innovative Gene Editing Technologies



In Vivo Precision Knock-In of Long Sequences” unveiled the potential of sequence-specific endonucleases for precision knock-ins of extensive DNA sequences within living organisms.

Dr. Shengjiang (Shawn) Liu’s presentation, “AAV Capsid Engineering for Ocular Gene Therapy” highlighted the promise of novel treatments for ocular diseases.

Dr. Guangming Wu presented “Rapid Generation of ACE2 Humanized Inbred Mouse Model for COVID-19 with Tetraploid Complementation,” demonstrating the swift development of an ACE2 humanized inbred mouse model critical to COVID-19 research.

During a session on ongoing


This webinar, hosted by ICC and STC of CABS on October 13, assembled leading experts in the field to discuss cutting-edge advancements in gene editing, animal models, and gene therapy.

Dr. Le Cong’s presentation “Beyond CRISPR: Metagenomic Mining of SSAP for

developments in gene therapy for β-Thalassemia, Dr. Lei Shi discussed “Gene Therapy for β-Thalassemia.”

Dr. Jiaoyang Sun delivered an engaging talk on “The Application of Turbomice™ Technology in Animal Models.” Dr. Sun explored the innovative Turbomice™ technology and its applications in creating advanced animal models for research, offering fresh perspectives in the field.

The webinar successfully attracted over 100 attendees, reflecting the widespread interest and importance of the topics discussed.



BioPacific Toastmasters Club Open House

The CABS-sponsored BioPacific Toastmasters Club successfully hosted a hybrid open house at Hanhai Biolabs in Burlingame on September 30, 2023. Four of our Toastmasters shared their experience in career transitioning and how their Toastmasters experience boosted their confidence and contributed to their success. The four wonderful speeches and the following Q&A session provided insightful information to the audience, as well as drawing great interest from guests in future Toastmasters meetings. Our club hosts a zoom meeting every Saturday, and a hybrid meeting on the 2nd Saturday of each month. For more information, please check out our website: biopacific.toastmastersclubs.org



ATON


Global
Biopharmaceutical
CDMO

Quality · Integrity · Efficiency · Excellence

Aton (Shanghai) Biotech Co., Ltd. is a rapidly growing biopharmaceutical Contract Development and Manufacturing Organization (CDMO). Aton prioritizes quality and is dedicated to empowering integrated biopharmaceutical drug development and manufacturing, enabling customers to accelerate their pipeline to market. Aton's services cover end-to-end CDMO services from cell line construction to commercial manufacturing, including the development and production of monoclonal antibodies, fusion proteins, bispecific antibodies, ADCs (Antibody Drug Coupling Compounds), etc. Now Aton is equipped with two R&D and manufacturing sites, supported by a quality management system that meets the requirements of the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and China's National Medical Products Administration (NMPA). In addition to the industry-leading manufacturing technology platform, Aton has established a first-in-class biopharmaceutical R&D, manufacturing, and operational management team with a high-quality talent reserve and a robust team structure. The core management team has an average of more than 15 years of senior management experience in the industry and possesses professional management expertise in R&D, clinical, manufacturing, CMC, quality, and compliance from leading multinational pharmaceutical companies.

Integrated Single Source CDMO Solution

for mAb / BsAb / Fusion Protein / ADC and more



Business Contact

021-33395966 | BD@atonbio.com
430 N McCarthy Blvd, Milpitas, CA 95035

Helping to drive innovation and growth for a healthier tomorrow

Innovation is at the heart of the life sciences industry. As partner to some of the leading life science innovators, MoFo supports your groundbreaking ideas and helps you discover the real-world solutions that will bring those ideas to life.

lifesciences.mofo.com

GenScript

MAKE RESEARCH EASY









Scan the QR Code to Learn More on www.genscript.com

+1-732-885-9188

860 Centennial Ave. Piscataway, NJ 08854 USA



-  GENE SERVICES
-  PEPTIDE SERVICES
-  REAGENT ANTIBODY SERVICES
-  PROTEIN SERVICES
-  CRISPR SERVICES
-  CATALOG PRODUCTS

Nona Biosciences Core Technology: Harbour Mice®



New Generation of Fully Human Antibody Platforms





Nona Biosciences is a global biotechnology company committed to providing innovative solutions for biologics drug discovery. Empowered by the industry leading fully antibody platform, the **Harbour Mice®**, which generates fully human monoclonal antibodies in both two heavy and two light chains (**H2L2**) and heavy chain only (**HCAb**) formats, is an effective and unique engine for generating next-gen therapeutics.



H2L2
Transgenic Mice



HCAb
Transgenic Mice

-  Worldwide patent protection
-  Validated by **50+** industry and academic partners
-  Applied in **200+** discovery programs
-  **14+** projects entered clinical stage

Next generation therapeutic modalities

- **Bispecific and multi-specific antibodies**
- **ADCs**
- **CAR-T**
- **mRNA therapies**

Please visit www.nonabio.com and contact BD@nonabio.com for more information.

JJ Lake Business Center is the innovative cross-border hub that enables entrepreneurs. We are located in both Mountain View, Silicon Valley, and Cambridge, Boston. We aim to foster innovation and growth through community events, investment partner collaborations and global market access. We provide international business development and fundraising consulting services to entrepreneurs.

Notably, we have an exclusive connection with Suzhou Industrial Park (SIP), and we have helped dozens of companies, including but not limited to those from biotech, semiconductors, nanotech, information, manufacturing industries, to initiate the local business.

So far, we have established a community of thousands of entrepreneurs and have successfully built up the relationship with hundreds of investment institutions.

Address: 340 E Middlefield Rd, Mountain View, CA 94043
 Web: www.jjlaker.com/Contact: Yifu Liu/E-mail: yifu@jjlaker.com



KACTUS

GMP MRNA ENZYMES

T7 RNA Polymerase
 Restriction Endonucleases
 RNase R
 DNase I

GENE EDITING REAGENTS

GMP Cas9 & Cas12a
 GMP MaxNuclease for DNA/RNA degradation
 AAV ELISA Kits

CELL THERAPY REAGENTS

Laminin 521 for iPSC culture
 Peptide-MHCs & Peptide-Ready MHCs
 Custom Soluble TCRs
 Human Wnt3a & Other Cytokines



GMP-GRADE ENZYMES



ISO13485 ACCREDITATION



FDA DRUG MASTER FILES



ACTIVITY TESTING



2500+ CATALOG PRODUCTS



MAMMALIAN EXPRESSION

Place your order today!

sales@kactusbio.us kactusbio.com

mispro

**Care at our core.
 Science at our center.**

The Bay Area's most trusted contract vivarium

mispro.com



PALO ALTO | SOUTH SAN FRANCISCO



www.pharmaron.com

PHARMARON is a leading, fully integrated pharmaceutical R&D services platform with global operations and has a well-established team of over 19,000 employees working in 20 different sites located in China, US and UK. Our mission is to support our partners' success in discovery, development and commercialization of innovative medicines.



Laboratory Services



Chemistry, Manufacturing and Control



Clinical Development



Biologics & CGT

- Synthetic Chemistry & Medicinal Chemistry
- Analytical Chemistry
- Computational Chem. & CADD
- DMPK/ADME
- Biology & Pharmacology
- Medical Device Evaluation
- Safety Assessment
- Process Chemistry & Analytical Dev.
- Material Science
- GMP API Manufacturing
- Formulation Development
- Drug Product Manufacturing
- Commercial-scale Manufacturing
- Radiolabelled Chemical Synthesis
- Clinical Bioanalysis (GCP)
- Radiolabelled Science
- Clinical Pharmacology (US-based)
- Clinical Development (China-based)
- Clinical SMO (China-based)
- Discovery Biologics
- Biologics CDMO
- CGT Lab Services
- CGT CDMO



AMGEN

Fighting the World's Toughest Diseases

BIOSYSTEMS
Acro



Recombinant Proteins



Antibodies



Assay Kits



Custom Services



GMP Manufacturing



Partner With Us

A Cornerstone of the Global Health & Biopharma Industries

 **Better Design**

 **Better Quality**

 **Better Support**

 **Better Response**

Bellen

Your "one-stop-shop" partner for innovative chemistry solutions

Tel: +1-650-504-8848
Email: charles.chen@bellenchem.com, sales@bellenchem.com
Website: www.bellenchem.com
Address: Building 9, Courtyard 10, Linhe Street, ShunYi District, Beijing, ShunYi District 101300, China

WuXi Biologics
Global Solution Provider

Unlock the Optimal Pairings of BsAb
Fast & Cost-Effectively



QUICK N' CLEAN - HTP small-scale BsAb production

Contact Us:  PS_Marketing@wuxibiologics.com


3h Science Essentials

Keywords: HPLC, LC/MS/MS, ELISA; method development & validation; stability studies; drug release.

3H Science Essentials (3H) is a Contract Research Organization (CRO) specializing in analytical & bioanalytical services from drug screening to preclinical through clinical studies.

3H scientists have 20+ years of experience developing and validating robust methods for many compounds including small & large molecules. Our clients and collaborations span fields ranging from academic/industrial research, drug discovery/development, to environmental services.

Please contact us via email or phone to learn more or schedule a visit.

3675 Enochs Street, Sata Clara, CA 95051
www.3hses.com
 Office: 408-685-2418;
 Mibile: 408-205-9332
 Visits/Info:
shuang@3hscienceessentials.com
 (Sunny Huang)




Meadowhawk
biolabs

Meadowhawk Biolabs Inc. is a bi-coastal preclinical CRO with biotech hubs in San Francisco and Boston. With a customer-centric mentality, we are committed to delivering high quality results in the shortest amount of time including local complimentary courier service to facilitate logistics.

Bioanalytical LC-MS Services
Sciex 7500

In Vivo Services
Rodent PK with Vivarium

Immunoanalytical Services
ELISA assays and MSD assays

Get In Touch: john.foster@meadowhawkbiolabs.com

meadowhawkbiolabs.com



Global Platform. One Vision.



Small Molecule Drug R&D and Manufacturing



Biologics R&D Drug R&D and Manufacturing



Cell Therapy and Gene Therapy



Medical Device Testing



Genomics and Molecular Diagnostics

WuXi's Vision

To become the most comprehensive capability and technology platform in the global pharmaceutical and healthcare industry to fulfill the dream that "every drug can be made and every disease can be treated."



 **FRONTAGE**

COMPREHENSIVE LABORATORY, ANALYTICAL, AND CLINICAL SERVICES

From Early Drug Discovery to Clinical Services

Medicinal Chemistry	Safety & Toxicology
Drug Screening	Bioanalytical
CMC	Central Lab
DMPK	Clinic

Harmonized Global Quality Standards, Systems, and Process in North America and China

frontagelab.com | sales@frontagelab.com

江苏无锡（惠山）生命科技产业园

Wuxi Huishan Life Science & Technology Industrial Park (L-PARK)



生命科技产业是技术、资金、人才密集型的高端产业，惠开经过多年的发展，形成了以高端创新药为主的细胞制药、医疗器械生产制造与企业孵化研发，健康医疗服务集中区，和以药明康德、保诺生物为主的中间体生产与医疗器械生产制造基地的空间布局，构建了以精准诊疗、高端医药、医疗器械三大领域的产业格局。

Life science and technology industry is a high-end industry with intensive technology, capital and talents. After years of development, it has formed a concentration area of cell pharmaceuticals, medical device manufacturing, enterprise incubation and research and development, and health care service, mainly focusing on high-end innovation drugs, a base for intermediate production and medical device manufacturing represented by Apptec and BoiDuro, building the industrial structure of integrating precision diagnosis and treatment, high-end medicine and medical equipment.

JOIN HUIZHAN CREATE THE FUTURE

Microcity

Huishan Economic Development Zone has established a development pattern of "four parks, one base and two centers" in terms of industrial layout, and formed five leading industries, including automobile and parts, high-end equipment manufacturing, new energy and new materials, life science and technology, and new generation information technology, which have comparative advantages and leading advantages.

In 2022, the total GDP of the region was 65 billion yuan, and the total income exceeded 300 billion yuan. The region entered the top 20 for the first time in the comprehensive assessment ranking of development zones in Jiangsu Province, which is the first choice.

Supporting policies

1. The total support for the English talent project is up to 3.5 million yuan.
2. The maximum subsidy for purchasing a house is 100,000 yuan.
3. Enjoy the international talents community, education of their children and employment of their spouses.
4. Talent services and credit support.

GemPharmatech

GemPharmatech developed world's largest and high-quality mouse model resources

We have generated the world's largest genetically modified mouse model repository, including humanized, germ-free, immunodeficient, conditional knockout (CKO), and knockout (KO) mouse models.

- Knockout All Project
- Disease Mouse Models
- Immunodeficient Mouse Models
- Humanized Immune Checkpoint Mouse Models
- Reliable, High-quality and Cost-effective Preclinical Services

11558 Sorrento Valley Rd, Ste 4, San Diego, CA 92121
 en.gempharmatech.com
 sales@gempharmatech.us
 +1 888-899-5899



We can't de-risk your entire project. Just one vital part of it.

Research antibodies need to perform as expected. Every time. Ours do. That's why six of the ten most-cited antibodies come from CST.* Researchers trust CST® products to provide reproducible results. You can, too. **Learn more at cellsignal.com**

© 2023 Cell Signaling Technology, Inc. All rights reserved. | All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information. For Research Use Only. Not for Use in Diagnostic Procedures. *CiteAb, "What were the top 100 research antibodies of 2022?" July, 2023. 23-BCH-79712






NevoGene

Advancing Genomics
Improving Life

Save on your next RNA and Epigenetics projects while at CABS 2023

Code: CABS2023*

Offer Includes one of the following: 50% Off ALL mRNA Analysis Packages, Free mRNA Library Preparation Upgrade (ask for details), and 20% Off WGBS, CHIP, RRBS. PLUS, Free shipping for all Discount Options*



OBio

OBio Tech, Inc.
www.obio-tech.com (USA)
(SSE: 688238.SH)

Your Trusted Cell & Gene Therapy CRO/CDMO Partner

8 FDA IND approvals
17 NMPA IND approvals
200+ Cell and Gene Therapy Programs
200+ Process Development Projects

Versatility for Variety

20 cGMP cell production lines
15 cGMP vector production lines

- Viral Vector
- Oncolytic Virus
- Cell Therapy
- Plasmid & Nucleotides



Connect with us on LinkedIn

bd@obio.com (USA) +1 (408) 807 5641 (USA)

TRAILBLAZING PATH TO SUB HUNDRED-DOLLAR GENOME

\$150 Genome
15,000 WGS per year

<\$100 Genome
50,000 WGS per year

Complete GENOMICS

BioPromind

Biologicals Logistics Services

- ❖ Biologicals
- ❖ Test Articles
- ❖ Cell Lines
- ❖ Animal Specimens
- ❖ Clinical Products

- Door-to-Door Shipment
- Shipping Paperwork
 - ✓ China Import/Export Permits
 - ✓ USDA/USFWS/CDC Permits
- Temperature Control
 - ✓ Liquid Nitrogen
 - ✓ Dry ice
 - ✓ Ice packs
 - ✓ Data logging

www.biopromind.com





Tigermed

Global Platform One Tigermed

Advance Human Health through Delivery Excellence

10,000+
Global Employees

120+
Global MRCT Projects

1,400+
Employees outside of China

49
Countries with employees

www.tigermedgrp.com info@tigermedgrp.com

Developing Cell Therapy with the Capacity to Cure Solid Tumors

EUREKA
THERAPEUTICS

Accelerate Your Cancer Research

Close to Home

Get to market faster
with our research-ready
resources

- Breeding, colony maintenance, and embryology services near the Bay Area
- Nine move-in ready CRADL® vivarium locations in San Francisco with included *in vivo* services

charles river

NOVOTECH™
The Asia Pacific CRO

CRO LEADERSHIP AWARD
Clinical Leader

BEST CRO FOR CELL & GENE THERAPY IN APAC
IMAPAC

BEST PRACTICES AWARD
Frost & Sullivan

Local relationships, global execution

Scan here

novotech-cro.com

**JOINN
Biologics** www.joinnbio.com

Your Trusted CDMO

One Stop from Cells to Market

2600 Hilltop Drive, Richmond, CA 94806 • (510) 295-0222 • info@joinnbio.com

JOINN BIOLOGICS

Mass Spectrometry

A complete line of turn-key services

Innomics now offers a complete line of mass spectrometry services for all your research and drug development needs. Our laboratory in San Jose, California is staffed by experienced scientists, equipped with cutting-edge LC-MS/MS instrumentation and advanced bioinformatics capabilities.

Genomics Transcriptomics Proteomics Peptidomics Metabolomics

DNBSEQ Platform Mass Spectrometry Platform

zonghui.peng@innomics.com, www.innomics.com
2904 Orchard Parkway, San Jose, CA 95134

Sino Biological's Bispecific Antibody Production Service

Service Highlights

- 20+BsAb formats can be produced
- High success rate
- Optimized HEK293/CHO platforms
- Various purification methods
- Powerful QC analysis
- Optimized efficient expression vector

Bispecific Antibody Expression Experience

BsAb Fragments: BITE, Diabody, Intrabody, Triple Body, scFv-CH3 KIH, Fab-scFv, scFv-CH-CL-scFv

BelgO: CrossMab, DutaMab, KIH-Common LC, LUZ-Y, kλ-body, scFv4-Ig, Diabody-Fc

Appended IgG: DVD-IgG, DVI-IgG, IgG(H)-scFv, IgG(L)-scFv, IgG(L)-V, scFv-(H)IgG, scFv-(L)IgG

Our Experience with Diverse BsAb Formats (The bsAb nomenclature - DOI: 10.1016/j.molimm.2015.01.003)

Thank You

TO OUR SPONSORS

CABS
CHINESE AMERICAN BIO/PHARMACEUTICAL SOCIETY
北美华人生物医药协会



CHINESE AMERICAN BIO/PHARMACEUTICAL SOCIETY (CABS)

Website: www.cabsweb.org

General information: Info@CABSweb.org

Membership: Membership@CABSweb.org

Fundraising: Fundraising@CABSweb.org

Mailing Address: 268 Bush Street, #1888, San Francisco, CA 94104, USA



[CABSweb.org](http://www.cabsweb.org)



[CABS Member Registration](#)



[CABS LinkedIn](#)



[CABS Newsletter](#)